



Universiteit
Leiden
The Netherlands

Targeting plasma cells in systemic autoimmune rheumatic diseases- Promises and pitfalls

Steinmetz, T.D.; Verstappen, G.M.; Suurmond, J.; Kroese, F.G.M.

Citation


Steinmetz, T. D., Verstappen, G. M., Suurmond, J., & Kroese, F. G. M. (2023). Targeting plasma cells in systemic autoimmune rheumatic diseases-Promises and pitfalls. *Immunology Letters*, 260, 44-57. doi:10.1016/j.imlet.2023.06.005

Version: Publisher's Version

License: [Creative Commons CC BY 4.0 license](#)

Downloaded from: <https://hdl.handle.net/1887/3665248>

Note: To cite this publication please use the final published version (if applicable).



Targeting plasma cells in systemic autoimmune rheumatic diseases – Promises and pitfalls

Tobit D. Steinmetz^{a,*}, Gwenny M. Verstappen^a, Jolien Suurmond^b, Frans G.M. Kroese^a

^a University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

^b Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands

ARTICLE INFO

Keywords:

Antibody-secreting cells
Plasma cells
Plasmablasts
Autoimmune rheumatic diseases
Treatment

ABSTRACT

Plasma cells are the antibody secretors of the immune system. Continuous antibody secretion over years can provide long-term immune protection but could also be held responsible for long-lasting autoimmunity in case of self-reactive plasma cells. Systemic autoimmune rheumatic diseases (ARD) affect multiple organ systems and are associated with a plethora of different autoantibodies. Two prototypic systemic ARDs are systemic lupus erythematosus (SLE) and Sjögren's disease (SjD). Both diseases are characterized by B-cell hyperactivity and the production of autoantibodies against nuclear antigens. Analogues to other immune cells, different subsets of plasma cells have been described. Plasma cell subsets are often defined dependent on their current state of maturation, that also depend on the precursor B-cell subset from which they derived. But, a universal definition of plasma cell subsets is not available so far. Furthermore, the ability for long-term survival and effector functions may differ, potentially in a disease-specific manner. Characterization of plasma cell subsets and their specificity in individual patients can help to choose a suitable targeting approach for either a broad or more selective plasma cell depletion. Targeting plasma cells in systemic ARDs is currently challenging because of side effects or varying depletion efficacies in the tissue. Recent developments, however, like antigen-specific targeting and CAR-T-cell therapy might open up major benefits for patients beyond current treatment options.

1. Introduction

Plasma cells are terminally differentiated B-cells and often described as antibody factories. Their intracellular compartments are specialized on mass protein production and distribution that makes their appearance fundamentally different to that of their B-cell precursors [1]. During plasma cell differentiation B-cells undergo many morphological, transcriptional and metabolic changes to become a functional plasma cell [2–5], that can persist and secrete antibodies for timespans between days and decades [6–8]. This long lifespan presumably also applies to autoreactive plasma cells that secrete potentially pathogenic antibodies targeted against self-antigens [9–11].

A plethora of different autoantibodies can be found in various systemic autoimmune rheumatic diseases (ARD). Systemic lupus

erythematosus (SLE), Sjögren's disease (SjD), rheumatoid arthritis (RA) and systemic sclerosis (SSc) are ARDs with systemic manifestations and organ involvement that supposedly share common mechanisms of B-cell alterations with similar outreach into the plasma cell compartment. However, these four diseases typically show differences in the organ that is most affected, namely joints, skin and exocrine glands in RA, SSc and SjD, respectively, while SLE can affect almost every organ. Depending on the organs affected, systemic ARDs can manifest cardiovascular, renal, cerebral, pulmonary, cutaneous, musculoskeletal or glandular complications [12–17]. While clinical phenotypes differ, shared underlying mechanisms for these systemic ARDs include the disturbance of immune tolerance leading to autoimmune reactions against nuclear and/or cytoplasmic self-antigens [18]. Autoreactive immune cells, including B- and T-lymphocytes, contribute to systemic

Abbreviations: APRIL, a proliferation-inducing ligand; BAFF, B-cell activating factor; BCMA, B-cell maturation antigen; BLIMP1, B lymphocyte-induced maturation protein-1; CD, cluster of differentiation; CXCR/L, cysteine-X-cysteine chemokine-receptor/-ligand; HLA, human leukocyte antigen; IL, interleukin; MALT, mucosa-associated lymphoid tissue; MHC, major histocompatibility complex; NFκB, nuclear factor kappa-light-chain-enhancer of activated B-cells; SSA/B, Sjögren's syndrome-related antigen A (Ro)/B (La); TACI, transmembrane activator and CAML interactor.

* Corresponding author at: University of Groningen, University Medical Center Groningen, Department of Rheumatology and Clinical Immunology, Hanzeplein 1, PO Box 30.001, 9700RB Groningen, The Netherlands.

E-mail address: d.t.steinmetz@umcg.nl (T.D. Steinmetz).

<https://doi.org/10.1016/j.imllet.2023.06.005>

Received 3 February 2023; Received in revised form 12 May 2023; Accepted 10 June 2023

Available online 12 June 2023

0165-2478/© 2023 The Author(s). Published by Elsevier B.V. on behalf of European Federation of Immunological Societies. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

abnormalities and initiate local, inflammatory processes that may lead to tissue destruction [19–21]. B-cell abnormalities are present in many ARDs and are for example reflected by altered distribution of peripheral B-cell subsets [22–24], lowered B-cell activation thresholds and increased risk of B-cell transformation into lymphomas [25]. Increased levels of serum IgG antibodies and various types of self-directed auto-antibodies are often considered part of these B-cell abnormalities. Consequently, B-cell-targeted therapies have been widely explored as a treatment option for systemic ARDs. However, most B-cell therapies do not directly affect plasmablasts and plasma cells (often jointly referred to as antibody-secreting cells), the cells which are solely responsible for antibody secretion. For the purpose of simplicity, this review will refer to all antibody-secreting cells as plasma cells.

This review will focus on the special characteristics of plasma cells, their subsets, what is known about their role in systemic ARDs, particularly SLE and SjD, and the promises and pitfalls of plasma cells as target population for treatment.

2. Who? – The origin of plasma cells

2.1. The origin of B-cells

B-cells originate in the bone marrow from hematopoietic stem cells (summarized in [26]). B-cell lymphopoiesis involves rearrangements of *variable*, *diversity* and *joining* genes that leave every B-cell with a unique B-cell receptor (BCR) out of 100 billion possible different specificities [27]. Given the mostly random nature of these rearrangements, many newly generated B-cells show capabilities to bind self-antigen [28]. To contain this autoreactive potential, central and peripheral tolerance checkpoints exist that remove autoreactive cells from the B-cell pool or induce an anergic state resulting in unresponsive autoreactive B-cells [29–31]. Tolerance mechanisms reduce the frequency of autoreactive B-cells from ~75% in the early stages to 10–20% in mature B-cells in healthy individuals [18,28,32,33].

2.2. Differentiation of B-cells into plasma cells

After their full maturation into naïve B-cells, antigen-specific activation can induce differentiation of B-cells into plasma cells. The nature of the antigen, BCR affinity, co-stimulatory signals during B-cell activation, and the B-cell subtype influence how B-cells differentiate towards plasma cells and might also affect the long-term fate of the resulting plasma cells. This differentiation can either be directly at extrafollicular sites, or indirectly after participation in germinal center reactions (overviewed in [34–40]).

Extrafollicular plasma cell formation occurs after BCR crosslinking and either toll-like receptor (TLR) engagement as additional signal and/or co-stimulation by T-cells. TLR signaling upregulates the TACI receptor, binding the two important B-cell cytokines BAFF and APRIL that induce isotype switching in synergy with BCR and TLR engagement [41]. Consequently, TACI engagement is necessary for adequate IgM and IgG responses against repetitive antigens (e.g., carbohydrate antigens) binding to the BCR, but to which T-cell cannot provide co-stimulation [42]. Elevated BAFF levels might therefore drive especially extrafollicular B-cell responses. In T-cell dependent responses, PD-1⁺CXCR5⁻ peripheral or PD-1⁺CXCR5⁺ follicular helper T-cells (T_{PH} or T_{FH}, respectively) can stimulate class switching and plasma cell differentiation outside or inside of follicles [43–45]. Different types of extrafollicular T_{PH} cells have been reported with different mechanisms (IL-21-dependent or -independent) to support plasma cell differentiation [46,47]. Plasma cells derived from extrafollicular responses are often short-lived and mainly secrete IgM or IgG depending on the presence of class switching signals and cellular origin (reviewed in [38]).

Germinal centers are highly organized structures that contain mainly B-cells, T_{FH}-cells and follicular dendritic cells (FDC) (see [48,49] for an overview). Germinal center B-cells rapidly proliferate and express

activation-induced deaminase (AID), an enzyme that is responsible for somatic hypermutation in the variable antibody region and isotype switching [50,51]. B-cells compete for antigen presented by FDCs and subsequently present the acquired antigen in the context of MHC class II molecules to obtain stimulatory signals from T_{FH}-cells [52–54]. Several rounds of mutation and selection raises the average B-cell affinity within a germinal center over time [55]. Higher antigen-affinities allow germinal center B-cells to take up more antigen from the FDCs, herewith presenting more antigen to CD4⁺ T-cells, and consequently are able to receive more co-stimulatory signals than low-affinity germinal center B-cells [56,57]. While germinal centers continuously generate memory B-cells [58,59], plasma cell differentiation requires higher antigen-affinities [60]. The germinal center B-cells with higher affinities receive more T-cell help, including stronger CD40 signaling. Only high levels of CD40 signaling induce high levels of interferon-regulatory factor 4 (IRF4) and subsequently Blimp1 [57], two important plasma cell transcription factors. Germinal center reactions frequently give rise to long-lived plasma cells, especially during late phases of immune reactions, that mostly produce IgG antibodies [58].

A classical immune reaction, e.g., towards pathogens or vaccinations, that initiates extrafollicular and germinal center derived plasma cell generation, produces a fast initial peak of antibodies for 2–4 weeks. While antibody levels typically decline to ~10% of the peak antibody response within months [61,62], it can then remain stable over decades [63]. Animal studies showed increased probability of long-lived plasma cell generation at the late stage of an immune reaction around a month after antigen exposure [64] corresponding to stable long-term antibody titers after vaccination in humans [65,66].

2.3. Tolerance during plasma cell differentiation

To protect the body from autoimmunity, autoreactive B-cells participating in germinal center reactions are prone to lose self-binding capacity gradually due to somatic hypermutations [67]. However, somatic hypermutation can also lead to *de novo* autoreactivity during germinal center reactions. Studies with monoclonal autoantibodies from B-cells and plasma cells from SLE or RA patients, respectively, revealed that reversion of the mutated configuration to their respective germline configuration led to reduced or lost binding capacities in at least a proportion of the tested autoantibodies [68,69]. In addition, defects of germinal center exclusion may exist in systemic ARDs [70–72]. In healthy individuals, B-cell autoreactivity is lower in post-germinal center cells, since lower frequencies of anti-nuclear antibody (ANA) reactive cells are observed in IgG memory compared to naïve B-cells in healthy controls [33]. This is likely regulated by T-cells, since T-cell help is required for proper germinal center B-cell responses. T-cell tolerance mediated by negative selection in the thymus during T-cell development is generally considered to be more stringent than for B-cells. Germinal center B-cells are additionally inhibited by follicular regulatory T-cells [73]. This concept of cognate antigen recognition by B- and T-cells serves as additional autoreactivity checkpoint in germinal centers [29].

2.4. Establishing the plasma cell identity

Plasma cells have a unique phenotype largely dedicated to protein production, including enlarged overall cell size, mitochondrial mass, endoplasmic reticulum (ER) and Golgi structures in comparison to their B-cell precursors [74,75] (Fig. 1). This plasma cell identity is induced and maintained by three main transcription factors: IRF4, already up-regulated in plasma cell precursors due to CD40 engagement [76,77], Blimp1, induced by IRF4 and cell division [78,79], and X-box binding protein 1 (XBP1), increased in response to ER protein overload [80,81]. IRF4 and Blimp-1 are both required for plasma cell differentiation. Additionally, IRF4 is required for maintenance of the plasma cell phenotype [82], whereas Blimp-1 and XBP-1 are important for the secretory function [83,84].




Fig. 1. Steady-state plasma cell niche. Stromal cells in bone marrow, spleen or other secondary lymphoid organs can form a long-term niche for plasma cells by providing integrins like VCAM and ICAM as anchors and cytokines like CXCL12. Additional support cells that may leave and rejoin the niche environment produce pro-survival factors for plasma cells like IL-6, BAFF and APRIL (input arrow). In turn, plasma cells facilitate long-term secretion of antibodies and cytokines (output arrow).

3. How? – Functions of plasma cells

3.1. (Auto)antibody secretion

The most well-known and dominant role of plasma cells is their capacity to produce antibodies. Since every plasma cell can produce up to 10,000 antibody molecules per second [85], the total plasma cell pool produces typically around 3–9 g IgA and 3 g IgG on a daily basis in healthy adults [86]. Some systemic ARDs like SLE and SjD are associated with increased total serum IgG levels (hypergammaglobulinemia), while RA and SSc show no IgG elevation or only in association with disease severity [87–89]. In general, it is thought that bone marrow plasma cells, with typically long-lasting lifespans, are the primary source of circulating antibodies [90], however, a specific location for long-term survival of autoantibody-producing plasma cells is not known yet. Both short- and long-lived autoreactive plasma cells are present in lupus mouse models, and in some mouse models, the spleen seems to represent a major source of autoreactive plasma cells [91]. Persistence of long-lived plasma cells additionally takes place in lymph nodes [92]. Increased numbers of circulating plasmablasts may also mirror autoantibody secretion in systemic ARDs [93–98].

3.2. Secretion of cytokines

Many studies show an important role of cytokine production by B-lineage cells. These cytokines can be pro- or anti-inflammatory, probably depending on the type of immune response or involved B-cell subsets (reviewed in [99]). Since plasma cells have a specialized machinery for protein production and secretion, it is conceivable that they can also produce high amounts of cytokines. Indeed there are plasma cells that produce high amounts of IL-10 and IL-35. These plasma cells are called regulatory plasma cells and are defined by expression of lymphocyte-activating gene 3 (LAG-3) [100]. These plasma cells can produce high amounts of IL-10 and IL-35 early during salmonella infection [101]. Likewise, IL-10 production by murine plasma cells has been shown in the context of experimental autoimmune encephalitis [102]. Studies with human B-cells show that a broad spectrum of B-cells secrete IL-10, including plasmablasts, but these findings mostly rely on

in vitro B-cell stimulation [103]. Other mouse studies suggested that murine plasma cells could be a major contributor to pro-inflammatory cytokine production, such as GM-CSF and IL-17 [104,105]. These studies should be interpreted with caution, as the plasma cell identity was not always unequivocally established. Nevertheless, it is likely that the type of cytokines produced by plasma cells depends on their stimulatory condition, e.g., due to a pro-inflammatory milieu. Functional studies into the specific role of cytokine production by plasma cells as opposed to total B-cells have not been reported to date. Therefore, it will be of interest to determine the relative contribution of plasma cells to pro- and anti-inflammatory cytokine production in health and disease.

4. When & where? – Maturation of plasma cells and the niche concept

4.1. Current assessment of maturity

The life-span of plasma cells has an enormous range from days to decades [8,106]. But the definition of markers that reflect their maturity and the potential lifetime of a plasma cell has been challenging. By distinguishing newly generated vaccine-specific plasmablasts and previously present plasma cells with non-vaccine specificity, a decrease in CD19, CD45 and MHCII but an increase of B-cell lymphoma protein 2 (Bcl2) and Blimp1 in plasma cells could be observed [107–109]. Additionally, Ki-67 is a common proliferation marker that identifies recently generated plasmablasts [109,110]. CD138 is part of murine plasma cell identification, because CD138 is expressed by all murine plasma cells [111]. However, human plasma cells are usually defined as CD27⁺CD38^{high} cells, also including plasmablasts, while excluding other immune cell markers like CD3, CD14 and/or CD16 [112]. Expression of CD138 is found on a proportion of circulating human plasma cells and the presence of CD138 is associated with other markers reflecting plasma cell maturity (e.g., lower CD20, CD45 or surface Ig expression), when compared to CD138⁻ plasma cells [110]. In mice, CD138 provides survival advantages for plasma cells by enhancing the utilization of pro-survival cytokines like IL-6 and APRIL [113]. Human CD138 has presumably similar functions, but also participates in cellular adhesion and migration (reviewed in [114]).

CD19 or CD138 alone or in combination are widely used to describe subtypes of plasma cells based on their maturity [7,109,115]. Stratification of bone marrow plasma cells using CD19 and CD138 revealed long-term antibody specificity against tetanus and measles only in CD19⁺CD138⁺ plasma cells, while CD19⁺CD138⁻ plasma cells contained influenza-specific cells and tetanus-specific cells just after a recent vaccination [115]. A study on CD27⁺CD38⁺ plasma cells in the duodenum used CD19 and CD45 to divide plasma cells into early (CD19⁺CD45⁺), intermediate (CD19⁻CD45⁺) and late (CD19⁻CD45⁻) stages. In line with their long lifespan, the frequency of late stage plasma cells increase with age within the duodenum whereas they were barely detectable at those sites in individuals younger than 20 years. Radioactive carbon (¹⁴C) dating indicated a median lifespan of late stage plasma cells of 22 years and high expression of CD28, CD56 and Bcl2 in this subset [7].

On the contrary, a study investigating vaccine-specific plasma cells found that CD19⁺ plasma cells contain cells specific for the eradicated vaccinia/smallpox virus [116]. Furthermore, circulating CD19⁻ and CD19⁺ plasma cells survived equally well *in vitro*. Those findings suggest that both subsets may have equal long-lived potential, and that it might be challenging to predict plasma cell survival based on CD19 expression [117,118].

4.2. A novel composite maturity index

Recently, we proposed a new methodology of assessing plasma cell maturity by combining four markers that were previously suggested to be regulated dependent on the maturity of plasma cells: CD19, HLA-DR, CD138 and CD28 [7,9,109,115]. To avoid a strict positive/negative cut-off approach, a continuous expression spectrum of those four markers by plasma cells was mapped by utilizing median fluorescence intensity values obtained by flow cytometry. Maturity ranks were assigned for the four markers individually and for each sample relative to the expression spectrum in the whole test cohort. By calculating the mean of those maturity ranks, a single plasma cell maturity-dependent value termed ‘maturity index’ was obtained [119]. Applying this novel approach to RNA-sequencing data of *in vitro* differentiating B-cells into plasma cells [120] showed a time-dependent increase of the maturity index. In a second validation attempt using a human blood plasma cell transcriptome dataset [75], a stepwise increase of the maturity index from CD19⁺CD138⁻ and CD19⁺CD138⁺ to CD19⁻CD138⁺ bone marrow plasma cells and a lower maturity index for blood plasma cells was observed [119].

Applying the newly developed maturity index to a cohort of Sjögren’s disease patients revealed a correlation of the maturity of circulating plasma cells with pro-inflammatory CXCR3 expression on plasma cells but also with increased salivary gland infiltration and ANA titers [119]. Using this novel maturity index to assess plasma cell maturity in systemic ARDs might identify patient subgroups that can benefit from specific mature or immature plasma cell targeting approaches. However, this proposed method currently uses bulk plasma cell metrics ignoring plasma cell heterogeneity and lacking comparability amongst different data sets. Therefore, a refined approach should take single plasma cell values into account and tackle inter-sample comparability along with further validation in larger study groups.

4.3. Steady-state plasma cell niches

Circulating but also tissue-resident plasma cells quickly die *in vitro* [121,122] despite their ability to achieve decade long lifespans *in vivo* [6,7]. The current lack of reports on plasma cell culturing techniques that keep plasma cells alive over month or years [118,122], suggest a complex mechanism of *in vivo* plasma cell survival that involves both plasma cell-intrinsic (e.g., CD138, CD28, and BCMA) and extrinsic factors. These factors cooperate in so-called plasma cell niches, tissue locations where plasma cells reside and survive for long time periods

(Fig. 1). This plasma cell niche usually involves an epithelial-like cell that is in direct contact with the plasma cell via integrins (reviewed in [5,80,123]). In the bone marrow, these niche-providing cells are stromal cells [122,124] that express vascular cell adhesion molecule (VCAM) and intercellular adhesion molecule (ICAM) integrins and CXCL12 to induce pro-survival signals in plasma cells [121,125]. Laminin β 1⁺ stromal cells are important specifically for IgG plasma cell niches in the bone marrow as seen in a *Salmonella* infection model [126].

Another important part of plasma cell niches are additional supporting cells that secrete pro-survival factors for plasma cells like APRIL and IL-6. This function was shown for basophils [127], megakaryocytes [128], dendritic cells, macrophages [129] and myeloid precursor cells [130]. Since those cell types have high turnover rates, their support function is likely transient and highly redundant. Additional redundancy exists between APRIL and BAFF [131], but the receptor with highest affinity for APRIL, BCMA, is fundamental for plasma cell survival while TACI and BAFF-receptor are dispensable [132].

Long-term plasma cell persistence and similar niche structures are described for lymph nodes [92], spleen [91], and mucosal tissues including tonsils and salivary glands [133–137]. Especially IgA plasma cells can persist in the long-term at mucosal sites (reviewed in [136]), thereby relying on mucosal specific markers like CCR9 and integrin α 4 β 7 to maintain their localization [138]. Healthy murine skin is another example of an alternative plasma cell niche hosting IgM⁺ plasma cells, but with yet unclear lifespan of those cells [139].

Though both intrinsic and extrinsic factors described above are required for survival of plasma cells, it is still unclear whether and how intrinsic factors for long-term survival are imprinted during plasma cell differentiation. Long-term plasma cell survival could also be a stochastic process. In that case, equally generated plasma cells would die at a random timepoint within their potential lifespan, resulting in short- and long-lived plasma cells. Subsets of circulating plasma cells have similar survival potential *in vitro* and share extensive clonal overlap [118] indicating those cells might have comparable survival imprinting. Likewise, it is unclear whether the maturation state of the plasma cells reflected by different markers (see Section 4.1) mirrors solely the kinetic of plasma cell differentiation or also predicts long-lived potential.

4.4. Induced *de novo* plasma cell niches in inflammation

Besides systemic, long-term secretion of protective antibodies, plasma cells also provide acute local immune protection at sites of inflammation. Local secretion of CXCL12 can attract CXCR4⁺ plasma cells to inflamed tissues to provide on-site antibody production [96,140,141]. Plasma cells can also upregulate CXCR3, presumably in response to interferon γ [142] that enables their homing towards CXCL9–11, chemokines frequently expressed in inflamed tissue [143]. As a consequence, CXCR3⁺ plasma cells are often described in inflammatory and autoimmune settings like infected skin [139], colitis [144], nephrotic kidneys [140] and arthritic synovium [145].

In addition to homing of plasma cells to sites of inflammation, several observations indicate the presence of long-lived plasma cells in inflamed tissues in *de novo* generated plasma cell niches, like clustered plasma cells in kidneys of SLE patients [146]. While salivary glands harbor IgA-specific cells as part of the healthy mucosal immune system [136,147], chronic autoimmune conditions like SjD shift the plasma cell composition towards IgG-specific [137] and autoantigen-specific cells [148]. Upregulation of integrins like α E β 7 [149] or laminin β 1 on submandibular duct cells [150] in SjD patients indicate a possible expansion of plasma cell niches in this autoimmune environment. In addition, salivary gland epithelial cells express ICAM, VCAM and CXCL12 similarly to bone marrow stroma cells [151].

Targeting pathogenic long-lived plasma cells gives the potential of a long-lasting disease amelioration, but the lack of definitive maturity-specific markers that reflect the lifespan of plasma cells and the location of plasma cells within tissues are substantial challenges for their

effective depletion. Therefore, a detailed characterization of plasma cells in individual patients might be required, to target the most pathogenic plasma cell populations while sparing as many protective plasma cells as possible.

5. What? - Disease specific properties of plasma cells in systemic ARDs

Systemic ARDs like SLE and SjD share broad alterations of the immune system including B-cell hyperactivity [87,152–155]. A prominent consequence of this B-cell hyperactivity is the general increase in circulating antibody levels (hypergammaglobulinemia) [156–158], serum free light chains [159,160] and high titers of various autoantibodies that may overlap between the diseases. Another feature reflecting systemic inflammation is an interferon signature, which is commonly observed in systemic ARDs in association with B-cell hyperactivity [21, 161,162]. Therefore, B-cell targeting therapies have been extensively studied in SLE and SjD.

SLE displays frequent inflammation of the skin and kidneys of patients, but many organs can be involved as well. The spectrum of disease manifestations is heterogeneous and the disease burden can range from mild to severe and switch between remission and flares with lupus nephritis among the most severe complications affecting a large group of patients (overviewed in [163–165]). SjD presents with characteristic inflammation of salivary and lacrimal glands including lymphocytic infiltration and organ damage that result in impaired tear and saliva production and the typical dryness symptoms [87]. Lymphocytic infiltrations in the glandular tissue, resulting in ectopic lymphoid tissues with germinal centers, a plasma cell isotype shift [166], B-cell driven hyperplasia of the epithelium (so-called lymphoepithelial lesions) [167] and an increased risk of B-cell lymphoma development, primarily of the MALT type, are histopathological hallmarks of the affected glands in SjD [168,169].

To date, treatment options for SLE and SjD are limited. In the case of severe organ manifestations, physicians rely on broad immunosuppression with traditional DMARDs (disease-modifying antirheumatic drugs) or rituximab, with variable efficacy. Although recently two targeted DMARDs have been approved for SLE, no DMARDs have been approved for SjD [170,171]. Plasma cell depletion approaches might open up novel treatment paths in both diseases. Hence we focus on plasma cell related similarities and differences in SLE and SjD that could be utilized for targeting.

5.1. Plasma cell related similarities between SLE and SjD

Multiple autoantibodies have been described in SLE and SjD patients with various ANAs, including anti-dsDNA, rheumatoid factor (RF), anti-SSA/Ro and anti-SSB/La antibodies (reviewed in [172,173]). Many of these antibodies can be present years before clinical symptom onset and diagnosis [174–176]. Anti-dsDNA and anti-Smith antibodies are thereby more specific for SLE, while SjD patients are frequently positive for anti-SSA and, to a lower extent, anti-SSB, rheumatoid factor or anti-muscarinic receptor antibodies [172,173]. Anti-dsDNA antibodies are considered pathogenic in SLE, while this is unclearly for other ANAs (reviewed in [177,178]). Animal studies indicate that anti-dsDNA antibodies can bind directly to mouse kidney glomeruli, and that monoclonal anti-dsDNA antibodies cause lupus nephritis [179]. In human disease, increases in anti-dsDNA antibodies frequently precede a disease flare [180–182]. For SjD, animal experiments indicate pathogenic properties of serum IgG from SjD patients by decreasing saliva production when injected into NOD.Igμ^{null} mice [183] and mice immunized with Ro/SSA-antigen show reduced saliva secretion [184]. In SjD patients, anti-Ro/SSA antibodies are indeed associated with impaired glandular functions [173].

SLE and SjD display overlapping B-cell alterations that influence plasma cell generation. B-cells from patients with SLE and SjD have

lower activation thresholds and express increased levels of the DNA-sensing receptor TLR9 [185,186], enhancing their potential to form plasma cells, likely by extrafollicular reactions [187]. Since the most common autoantigens (e.g., ribonucleoproteins like SSA/Ro) in SLE and SjD can trigger the B-cell receptor and TLRs simultaneously [177], IgG isotype switching can also take place independent from T-cells [188]. Furthermore, CD27⁺ IgD⁻CD11c⁺ double negative (DN2) B-cells are frequently involved in extrafollicular reactions and commonly increased in SLE and SjD and show higher TLR7 signaling [23,189,190]. DN2 B-cells are described as direct plasma cell precursor cells in healthy individuals as well as SLE patients [38,191,192]. In addition, ectopic lymphoid structures are also present in inflammatory environments like SLE kidneys and SjD salivary glands with fully organized germinal centers including B- and T_{FH}-cells, FDCs and AID expression (overviewed in [193,194]). T_{FH}-cells are significantly increased in blood and target tissue of patients with SLE and SjD likely supporting elevated germinal center activity and plasma cell output [43,195–197]. However, peripheral helper T_{PH}-cell frequencies (as the extrafollicular counterparts of T_{FH}-cells) and their different subtypes also correlate with plasma cells in SLE and SjD [43,46,47,198].

Taken together, a main question remains if autoantibodies primarily originate from extrafollicular or germinal center responses or both, as this might influence the lifespan of the corresponding plasma cells, and if both responses play different roles in systemic ARDs. An additional open question is whether tissue plasma cells immigrated from blood or differentiate locally either via extrafollicular or germinal center pathways.

5.2. Plasma cell abnormalities in SLE

5.2.1. Circulating plasma cells in SLE

The frequencies of total blood plasma cells (plasmablasts and long-lived plasma cells) in SLE patients correlate with disease activity [93, 94,199]. An altered plasma cell transcriptome associates especially with musculoskeletal and renal disease [200]. ANA-reactive plasma cells are also expanded in the blood of many SLE patients, in a relatively stable frequency [201]. The total plasma cell population in SLE blood samples shows an altered phenotype, compared to healthy individuals, that includes increased expression of HLA-DR [202] and CD38 [203]. Abundance of newly generated HLA-DR^{high}CD27^{high} cells, likely representing plasmablasts, correlates to disease activity and anti-dsDNA antibody titers [202], indicating that plasma cell formation is an ongoing process. Treatment of SLE patients with the anti-CD20 antibody rituximab (with or without additional belimumab) decreased anti-dsDNA titers [178]. Since CD20 is expressed on plasmablasts, this argues for plasmablasts as a major population secreting anti-dsDNA autoantibodies. In addition, class-switched plasmablasts show low mutation rates [204] and increased TLR9 expression [205] in active SLE patients suggesting they might originate from extrafollicular activation.

5.2.2. Renal plasma cells in SLE

Renal involvement and nephritis are common and serious conditions in SLE [164]. While circulating autoantibodies can bind to exposed chromatin in kidney glomeruli [179], local infiltration of immune cells including plasma cells are commonly described in SLE patients [146, 206]. Numbers of plasma cells in blood and kidney are higher in SLE patients with severe nephritis, compared to patients without nephritis [94]. A tissue transcriptome study in SLE patients reported kidney plasma cells to resemble a phenotype similar to long-lived bone marrow plasma cells after induction of standard treatment while untreated patients showed mainly plasma cells with genes upregulated in short-lived plasma cells [207]. This might suggest an impact of treatment on B-cell to plasma cell maturation that diminishes ongoing generation of plasmablasts while already generated plasma cells might continue to mature. These long-lived renal plasma cells might contribute to relapse of nephritis in some patients. However, an animal study using adoptive

transfer of long-lived plasma cells into lymphocyte deficient mice (Rag1^{-/-}) showed preferential homing of those cells to the bone marrow and spleen niches, with onset of nephritis with immune complexes and reduced survival after 20 weeks post transfer [208]. This indicates that the presence of plasma cells is not required for kidney malfunctioning, and that pathogenic plasma cells can be located outside the kidney. This is in line with findings of the accelerating medicines partnership (AMP) study, where no in situ differentiation of plasma cells in the kidneys of lupus nephritis patients was found [209].

5.3. Plasma cell abnormalities in SjD

5.3.1. Circulating plasma cells in SjD

We and others have shown that SjD patients have increased frequencies of plasma cells in peripheral blood, that might be associated with presence of anti-Ro/SSA antibody [210], lymphocytic salivary gland infiltrations (focus score) [95,119,210] or presence of lymphoepithelial lesions [119]. T_{FH}-cell numbers in blood [211] and salivary glands [197] are elevated in SjD patients. This might explain higher plasma cell frequencies, since T-cells from SjD patients also show increased capabilities to induce a plasma cell phenotype when cultured with B-cells [212]. Circulating plasma cells in SjD patients also display a more mature CD19-negative phenotype [95,119] that remains stable even after an immune stimulus like a vaccination [22]. Since rituximab only moderately lowers anti-SSA serum levels [213–215], the majority of those antibodies might either originate from long-lived plasma cells or rituximab-resistant plasmablasts in tissues (see Section 6).

5.3.2. Glandular plasma cells in SjD

SjD is a systemic condition, but the salivary glands are the main inflammatory hotspot. Plasma cells are part of normal mucosal immunity in salivary glands [136], but in SjD patients the isotype composition change from IgA dominance towards a higher frequency of IgG plasma cells [96,137], called plasma cell shift [166,216]. These IgG plasma cells are either the result of infiltration [217], local generation, likely in association with the amount of lymphocytic infiltrates or both [96,217]. Local production of autoantibodies against SSA/Ro and SSB/La antigens was shown for all Ig isotypes [148]. A notion that plasma cells in the salivary gland of SjD patients are located in the vicinity of CXCL12- and IL-6-producing cells might indicate the formation of *de novo* plasma cell niches in SjD [96] either additional to the physiologic IgA plasma cell niche or in competition with it. An animal model of SjD suggests the accumulation of long-lived, non-dividing plasma cells in salivary glands of NOD.B10.H2b mice during the progression of the disease [218], further indicating the potential development of survival niches in salivary glands.

5.3.3. B- and plasma cell derailment in SjD

A prominent result of B-cell hyperactivity in SjD is lymphoma development, especially of the MALT type (reviewed in [168]). High focus scores and rheumatoid factor (reviewed in [162]) but also monoclonal gammopathy of undetermined significance (MGUS) are risk factors for developing lymphoma [169,219]. Although MGUS is rare in SjD with a prevalence of 1.5% [220], SjD elevates the risk for its development [221]. Additionally, MGUS is considered as a potential precursor of multiple myeloma (MM) and SjD patients with MGUS show indeed a higher risk for MM development [219]. In general, SjD patient have a higher risk to develop MM [221,222] that further increases for patients positive for anti-SSA/Ro and anti-SSB/La antibodies [222]. Increased MM development might be an additional indicator of pathogenic, plasma cell-intrinsic abnormalities in SjD.

6. What to do? - Options for plasma cell targeting

Multiple therapeutic strategies directed at B-cells have been approved or are currently under evaluation for the treatment of systemic

ARDs. B-cell-targeted therapies can also affect the plasma cell compartment (particularly plasmablasts), by depletion of plasma cell precursors (e.g., rituximab – anti-CD20), inhibition of plasma cell differentiation (e.g., belimumab - anti-BAFF, atacicept - anti-BAFF/APRIL), or both (e.g., ivalumab - anti-BAFF-receptor). These therapies generally do not affect long-lived plasma cells, as shown for rituximab [223, 224], which could partially explain the low rates of efficacy for most of the B-cell-targeted therapies in SLE and SjD. Direct inhibition of (autoreactive) plasma cells might be an alternative therapeutic approach to attenuate disease (Fig. 2), in particular in patients with refractory disease after B-cell-targeting treatment. However, the design of plasma cell-targeted therapies has been challenging. Here, we outline different promises and pitfalls of possible approaches.

6.1. Proteasome inhibition

Newly produced proteins in plasma cells need to be folded correctly in the ER and misfolded proteins are degraded by the ubiquitin-proteasome pathway. Regulatory proteins, including cell cycle regulators, are also degraded via this pathway and proteasome inhibition consequently leads to the accumulation of cell cycle regulatory proteins causing higher sensitivity to apoptosis. Proteasome inhibition also blocks NFκB signaling (reviewed in [225]), but NFκB activation is an important pathway for long-term plasma cell survival [121].

The first generation proteasome inhibitor bortezomib shows profound reduction of anti-dsDNA antibodies and total plasma cells by half in SLE patients. At the same time, protective vaccine-specific and total immunoglobulin levels in the serum were reduced by 25–30% [226, 227]. Additionally, proteasome inhibition lacks plasma cell specificity, resulting in side effects. Bortezomib treatment, for example, increases the risk of neuropathy and cardiovascular events [228]. Although there are a couple of case reports on successful use of bortezomib in SLE and SjD patients [226,229], its safety profile seems unfavorable for wide application in patients with systemic ARDs.

6.2. Therapeutic antibodies

While conventional B-cell markers, such as CD19 and CD20, are downregulated at different stages of plasma cell maturation, other surface markers are upregulated [7,109]. These upregulated cell surface markers can be used for plasma cell depletion using therapeutic monoclonal antibodies. Examples of such therapeutic antibodies that have been used to target plasma cells, mostly in the context of multiple myeloma, are anti-CD38 (e.g., daratumumab [230]), anti-SlamF7 (elotuzumab [231]) and anti-BCMA (e.g., belantamab [232]). Especially CD38 and SlamF7 are not selectively expressed by plasma cells, which could result in both advantages and disadvantages for the treatment of systemic ARDs. SlamF7 is also expressed by activated, naïve B-cells and DN2 B-cells as shown in SLE patients [23], and targeting these cells along with plasma cells may be beneficial. However, simultaneous targeting of other CD38- or SlamF7-positive immune cells may be less desirable (e.g., regulatory B- and T-cells in the case of anti-CD38 [230] and natural killer cells in the case of anti-SlamF7 [233,234]). BCMA expression is more specific to plasma cells than CD38 or SlamF7 and has been applied in the field of MM as antibody-drug conjugate, together with a cytotoxic agent (monomethyl auristatin F) [232], or as part of an anti-BCMA/CD3 bispecific antibody that directly engages T-cells to stimulate killing of neoplastic plasma cells [235]. Since BCMA targeting focuses more on long-lived plasma cells due to its expression pattern, it has to be clarified whether pathogenic plasma cells originating from sources like extrafollicular responses, with potentially shorter lifespans, are sufficiently addressed by this approach in different systemic ARDs.

So far, clinical response on daratumumab treatment has been shown in cases of SLE patients mostly with refractory, life-threatening disease and treatment was well-tolerated [203,236], although anti-tetanus and total IgG antibodies were additionally reduced [203]. Daratumumab




Fig. 2. Approved drugs with plasma cell-targeting potential. Overview of targetable proteins with decreasing (CD19, CD20, BAFF-receptor; green background) or increasing expression (BCMA, SlamF7; red background) during plasma cell maturation or present on all plasma cells (CD38, TACI, Proteasome; yellow background). Corresponding treatment options with clinically-approved therapeutics that have potential for targeting of plasma cells in systemic autoimmune rheumatic diseases are indicated. Monoclonal antibodies mediate antibody-dependent or complement-dependent cytotoxicity, CAR-T-cells directly deplete target cells, while proteasome inhibitors and APRIL/BAFF blockade interfere with survival signals.

efficiently depletes none-neoplastic plasma cells below detectable frequencies in MM patients [237]. Broad depletion implicates potential risks for patients with systemic ARDs, due to higher susceptibility to infections if also protective plasma cells are depleted.

6.3. CAR-T-cell therapy

Chimeric antigen receptor T-cell (CAR-T) therapy has shown great potential for the treatment of various malignancies. The working mechanism of CAR-T therapy include genetic modification of a patient's CD8⁺ T-cells to express a modified antibody molecule as surface receptor (hence chimeric antigen receptor), which enables attachment to and killing of the target cell. An example of a plasma cell-specific antigen that has been used in CAR-T therapy for MM is BCMA [238], yielding almost complete depletion of plasma cells [239] and herewith a severe reduction of serum immunoglobulins in case reports [240]. In addition to the field of oncology, CAR-T therapy is also increasingly used in other diseases, including systemic ARDs. Anti-CD19 CAR-T-cell treatment of patients with refractory SLE resulted in drug-free remission with disappearance of B-cells from peripheral blood, improvement of clinical symptoms and normalization of serological parameters including conversion of anti-dsDNA and anti-Smith antibodies levels below detection limits [241]. The safety profile also seems favorable with only a mild cytokine-release syndrome in some of the treated patients. Another study using anti-CD19 CAR-T-cells reported efficient depletion of bone marrow plasma cells in children but not in adults [242]. Provided that plasma cells in children might not have had enough time to fully mature yet, this CD19 CAR-T-cell study would imply that mature plasma cells are spared from deletion. Therefore, anti-CD19 CAR-T-cell therapy might be a promising and effective approach for systemic ARDs with a dominant plasmablast and extrafollicular plasma cell component, but might have limited effects on diseases with higher contribution from long-lived (bone marrow) plasma cells. Also, high costs might restrain broad application of CAR-T therapy in patients with systemic ARDs.

6.4. Antigen specific targeting

To prevent depletion of protective plasma cells, an ideal strategy for autoimmune diseases would be a selective depletion of plasma cells based on their antigen specificity. Although such therapies have not yet been tested in humans, plasma cell depletion in an ovalbumin (OVA)-vaccinated mouse model using OVA-conjugated anti-CD138 antibodies resulted in a specific depletion of the majority of OVA-specific bone marrow plasma cells [243]. In principle, this anti-CD138/OVA conjugate binds to all plasma cells that express the respective CD138 marker, but only plasma cells that secrete OVA-specific antibodies opsonize their own cell surface. Following this, OVA-specific plasma cells are depleted by mechanisms similar to the use of therapeutic antibodies [244]. Whether antigen-specific plasma cell targeting can be applied in humans remains to be shown.

7. Perspectives

Plasma cells have been receiving increased attention over the last years as potential contributors to systemic ARDs with more reports covering plasma cell specific research questions. However, plasma cells can differ in lifespan and surface marker expression. Their decade-long survival potential and specialized tissue environments are beneficial traits for protective plasma cells but also raise the bar for efficient plasma cell depletion. Varying plasma cell lifespans and associated marker expression might require adapted targeting strategies potentially differing among systemic ARDs. Advances in oncology, especially in the treatment of multiple myeloma, have generated a broad toolbox of potential plasma cell treatments that are starting to be utilized in the field of systemic ARDs. Future studies on disease- and patient-specific plasma cell characteristics could open up additional and effective treatment options for patients that do not benefit from current treatment schemes.

Declaration of Competing Interest

G. M. Verstappen and F.G.M. Kroese are consultants for ArgenX. T.D. Steinmetz and J. Suurmond have no conflict of interest to declare.

Acknowledgements

This work is funded by a grant from the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) – project number 456067883 to TDS. This publication is part of project number 09150162010166 of the Veni research program to GMV, which is financed by the Dutch Research Council (NWO). JS received funding from the Leiden University Medical Center (internal MSCA Seal-of-Excellence 2020 regulation). Several authors of this publication are members of the European Reference Network ERN ReCONNET.

References

- [1] D.R. Fooksman, T.A. Schwickert, G.D. Victora, M.L. Dustin, M.C. Nussenzweig, D. Skokos, Development and migration of plasma cells in the mouse lymph node, *Immunity* 33 (2010) 118–127, <https://doi.org/10.1016/j.immuni.2010.06.015>.
- [2] B.T. Gaudette, D. Allman, Biochemical coordination of plasma cell genesis, *Immunol. Rev.* 303 (2021) 52–61, <https://doi.org/10.1111/imr.12992>.
- [3] G.K. Manakkat Vijay, H. Singh, Cell fate dynamics and genomic programming of plasma cell precursors, *Immunol. Rev.* 303 (2021) 62–71, <https://doi.org/10.1111/imr.13010>.
- [4] S. Trezise, S.L. Nutt, The gene regulatory network controlling plasma cell function, *Immunol. Rev.* 303 (2021) 23–34, <https://doi.org/10.1111/imr.12988>.
- [5] S.L. Nutt, P.D. Hodgkin, D.M. Tarlinton, L.M. Corcoran, The generation of antibody-secreting plasma cells, *Nat. Rev. Immunol.* 15 (2015) 160–171, <https://doi.org/10.1038/nri3795>.
- [6] E. Hammarlund, A. Thomas, L.J. Amanna, L.A. Holden, O.D. Slayden, B. Park, L. Gao, M.K. Slifka, Plasma cell survival in the absence of B cell memory, *Nat. Commun.* 8 (2017) 1781, <https://doi.org/10.1038/s41467-017-01901-w>.
- [7] O.J.B. Landsverk, O. Snir, R.B. Casado, L. Richter, J.E. Mold, P. Réu, R. Horneland, V. Paulsen, S. Yaquib, E.M. Aandahl, O.M. Øyen, H.S. Thorarensen, M. Salehpour, G. Possner, J. Frisén, L.M. Sollid, E.S. Baekkevold, F.L. Jahnsen, Antibody-secreting plasma cells persist for decades in human intestine, *J. Exp. Med.* 214 (2017) 309–317, <https://doi.org/10.1084/jem.20161590>.
- [8] R.A. Manz, A. Thiel, A. Radbruch, Lifetime of plasma cells in the bone marrow, *Nature* 388 (1997) 133–134, <https://doi.org/10.1038/40540>.
- [9] B.F. Hoyer, R.A. Manz, A. Radbruch, F. Hiepe, Long-lived plasma cells and their contribution to autoimmunity, *Ann. N. Y. Acad. Sci.* 1050 (2005) 124–133, <https://doi.org/10.1196/annals.1313.014>.
- [10] F. Hiepe, T. Dörner, A.E. Hauser, B.F. Hoyer, H. Mei, A. Radbruch, Long-lived autoreactive plasma cells drive persistent autoimmune inflammation, *Nat. Rev. Rheumatol.* 7 (2011) 170–178, <https://doi.org/10.1038/nrrheum.2011.1>.
- [11] H.D. Chang, K. Tokoyoda, B. Hoyer, T. Alexander, L. Khodadadi, H. Mei, T. Dörner, F. Hiepe, G.R. Burmester, A. Radbruch, Pathogenic memory plasma cells in autoimmunity, *Curr. Opin. Immunol.* 61 (2019) 86–91, <https://doi.org/10.1016/j.coi.2019.09.005>.
- [12] L. Stojanovich, B. Milovanovich, S.R. de Luka, D. Popovich-Kuzmanovich, V. Bisenich, B. Djukanovich, T. Randjelovich, M. Krotin, Cardiovascular autonomic dysfunction in systemic lupus, rheumatoid arthritis, primary Sjögren syndrome and other autoimmune diseases, *Lupus* 16 (2007) 181–185, <https://doi.org/10.1177/0961203306076223>.
- [13] J.Y. Streifler, Y. Molad, Chapter 30 - connective tissue disorders: systemic lupus erythematosus, Sjögren's syndrome, and scleroderma, in: J. Biller, J.M. Ferro (Eds.), *Handb. Clin. Neurol.*, Elsevier, 2014, pp. 463–473, <https://doi.org/10.1016/B978-0-7020-4086-3.00030-8>.
- [14] T. Jacques, I. Sudoi-Szopińska, N. Larkman, P. O'Connor, A. Cotten, Musculoskeletal manifestations of non-RA connective tissue diseases: scleroderma, systemic lupus erythematosus, still's disease, dermatomyositis/polymyositis, Sjögren's syndrome, and mixed connective tissue disease, *Semin. Musculoskelet. Radiol.* 22 (2018) 166–179, <https://doi.org/10.1055/s-0038-1639473>.
- [15] S.C. Mathai, S.K. Danoff, Management of interstitial lung disease associated with connective tissue disease, *BMJ* 352 (2016) h6819, <https://doi.org/10.1136/bmj.h6819>.
- [16] A. Kronbichler, G. Mayer, Renal involvement in autoimmune connective tissue diseases, *BMC Med.* 11 (2013) 95, <https://doi.org/10.1186/1741-7015-11-95>.
- [17] S. Rashtak, M.R. Pittelkow, Skin involvement in systemic autoimmune diseases, *Dermatol. Immunol.* 10 (2008) 344–358, <https://doi.org/10.1159/000131754>.
- [18] S. Glauzy, B. Olson, C.K. May, D. Parisi, C. Massad, J.E. Hansen, C. Ryu, E. L. Herzog, E. Meffre, Defective early B cell tolerance checkpoints in patients with systemic sclerosis allow the production of self antigen-specific clones, *Arthritis Rheumatol.* 74 (2022) 307–317, <https://doi.org/10.1002/art.41927>.
- [19] D. Yu, L.S.K. Walker, Z. Liu, M.A. Linterman, Z. Li, Targeting TFH cells in human diseases and vaccination: rationale and practice, *Nat. Immunol.* 23 (2022) 1157–1168, <https://doi.org/10.1038/s41590-022-01253-8>.
- [20] J.H. Reed, G.M. Verstappen, M. Rischmueller, V.L. Bryant, When B cells break bad: development of pathogenic B cells in Sjögren's syndrome, *Clin. Exp. Rheumatol.* 38 (Suppl 126) (2020) 271–282.
- [21] B.W. Higgins, Z. Liu, B. White, W. Zhu, W.I. White, C. Morehouse, P. Brohawn, P. A. Kiener, L. Richman, D. Fiorentino, S.A. Greenberg, B. Jallal, Y. Yao, Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway, *Ann. Rheum. Dis.* 70 (2011) 2029–2036, <https://doi.org/10.1136/ard.2011.150326>.
- [22] T.D. Steinmetz, L. de Wolff, J.H. Terpstra, A. Visser, H. Bootsma, F.G.M. Kroese, G.M. Verstappen, Immunisation with Coronavirus-2 vaccines induces potent antibody responses and does not aggravate the lymphocyte compartment of primary Sjögren's syndrome patients, *Clin. Exp. Rheumatol.* (2022), <https://doi.org/10.55563/clinexprheumatol/1iaqnu>.
- [23] S.A. Jenks, K.S. Cashman, E. Zumaquero, U.M. Marigorta, A.V. Patel, X. Wang, D. Tomar, M.C. Woodruff, Z. Simon, R. Bugrovsky, E.L. Blalock, C.D. Scharer, C. M. Tipton, C. Wei, S.S. Lim, M. Petri, B. Niewold, J.H. Anolik, G. Gibson, F.E.-H. Lee, J.M. Boss, F.E. Lund, I. Sanz, Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus, *Immunity* 49 (2018) 725–739, <https://doi.org/10.1016/j.immuni.2018.08.015>, e6.
- [24] D. Simon, P. Balogh, A. Bognár, Z. Kellermayer, P. Engelmann, P. Németh, N. Farkas, T. Minier, V. Lóránd, L. Cziráj, T. Berki, Reduced non-switched memory B cell subsets cause imbalance in B cell repertoire in systemic sclerosis, *Clin. Exp. Rheumatol.* 34 (100) (2016) 30–36. Suppl.
- [25] E. Zintzaras, M. Voulgarelis, H.M. Moutsopoulos, The risk of lymphoma development in autoimmune diseases: a meta-analysis, *Arch. Intern. Med.* 165 (2005) 2337–2344, <https://doi.org/10.1001/archinte.165.20.2337>.
- [26] R. Grosschedl, Establishment and maintenance of B Cell identity, *Cold Spring Harb. Symp. Quant. Biol.* 78 (2013) 23–30, <https://doi.org/10.1101/sqb.2013.78.020057>.
- [27] M. Nishana, S.C. Raghavan, Role of recombination activating genes in the generation of antigen receptor diversity and beyond, *Immunology* 137 (2012) 271–281, <https://doi.org/10.1111/imm.12009>.
- [28] H. Wardemann, S. Yurasov, A. Schaefer, J.W. Young, E. Meffre, M. C. Nussenzweig, Predominant autoantibody production by early human B cell precursors, *Science* 301 (2003) 1374–1377, <https://doi.org/10.1126/science.1086907>.
- [29] F. Melchers, Checkpoints that control B cell development, *J. Clin. Invest.* 125 (2015) 2203–2210, <https://doi.org/10.1172/JCI78083>.
- [30] C.G. Bonasia, W.H. Abdulahad, A. Rutgers, P. Heeringa, N.A. Bos, B cell activation and escape of tolerance checkpoints: recent insights from studying autoreactive B cells, *Cells* 10 (2021) 1190, <https://doi.org/10.3390/cells10051190>.
- [31] R. Halverson, R.M. Torres, R. Pelanda, Receptor editing is the main mechanism of B cell tolerance toward membrane antigens, *Nat. Immunol.* 5 (2004) 645–650, <https://doi.org/10.1038/ni1076>.
- [32] S. Malkiel, V. Jegannathan, S. Wolfson, N. Manjarrez Orduño, E. Marasco, C. Aranow, M. Mackay, P.K. Gregersen, B. Diamond, Checkpoints for autoreactive B cells in the peripheral blood of lupus patients assessed by flow cytometry, *Arthritis Rheumatol.* 68 (2016) 2210–2220, <https://doi.org/10.1002/art.39710>.
- [33] J. Suurmond, Y. Atisha-Fregoso, E. Marasco, A.N. Barlev, N. Ahmed, S. A. Calderon, M.Y. Wong, M.C. Mackay, C. Aranow, B. Diamond, Loss of an IgG plasma cell checkpoint in patients with lupus, *J. Allergy Clin. Immunol.* 143 (2019) 1586–1597, <https://doi.org/10.1016/j.jaci.2018.10.041>.
- [34] J.G. Cyster, B cell follicles and antigen encounters of the third kind, *Nat. Immunol.* 11 (2010) 989–996, <https://doi.org/10.1038/ni.1946>.
- [35] T. Okada, J.G. Cyster, B cell migration and interactions in the early phase of antibody responses, *Curr. Opin. Immunol.* 18 (2006) 278–285, <https://doi.org/10.1016/j.coi.2006.02.005>.
- [36] H. Qi, J.G. Egen, A.Y.C. Huang, R.N. Germain, Extrafollicular activation of lymph node B cells by antigen-bearing dendritic cells, *Science* 312 (2006) 1672–1676, <https://doi.org/10.1126/science.1125703>.
- [37] B.W. Higgins, L.J. McHeyzer-Williams, M.G. McHeyzer-Williams, Programming isotype-specific plasma cell function, *Trends Immunol.* 40 (2019) 345–357, <https://doi.org/10.1016/j.it.2019.01.012>.
- [38] S.A. Jenks, K.S. Cashman, M.C. Woodruff, F.E.-H. Lee, I. Sanz, Extrafollicular responses in humans and SLE, *Immunol. Rev.* 288 (2019) 136–148, <https://doi.org/10.1111/imr.12741>.
- [39] T.D. Chan, D. Gatto, K. Wood, T. Camidge, A. Basten, R. Brink, Antigen affinity controls rapid T-dependent antibody production by driving the expansion rather than the differentiation or extrafollicular migration of early plasmablasts, *J. Immunol.* 183 (2009) 3139–3149, <https://doi.org/10.4049/jimmunol.0901690>.
- [40] T.G. Phan, D. Paus, T.D. Chan, M.L. Turner, S.L. Nutt, A. Basten, R. Brink, High affinity germinal center B cells are actively selected into the plasma cell compartment, *J. Exp. Med.* 203 (2006) 2419–2424, <https://doi.org/10.1084/jem.20061254>.
- [41] B. He, R. Santamaria, W. Xu, M. Cols, K. Chen, I. Puga, M. Shan, H. Xiong, J. B. Bussel, A. Chiu, A. Puel, J. Reichenbach, L. Marodi, R. Döflinger, J. Vasconcelos, A. Issekutz, J. Krause, G. Davies, X. Li, B. Grimbacher, A. Plebani, E. Meffre, C. Picard, C. Cunningham-Rundles, J.L. Casanova, A. Cerutti, The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88, *Nat. Immunol.* 11 (2010) 836–845, <https://doi.org/10.1038/ni.1914>.
- [42] G.U. von Bülow, J.M. van Deursen, R.J. Bram, Regulation of the T-independent humoral response by TACI, *Immunity* 14 (2001) 573–582, [https://doi.org/10.1016/S1074-7613\(01\)00130-3](https://doi.org/10.1016/S1074-7613(01)00130-3).

- [43] A.V. Bocharnikov, J. Keegan, V.S. Wacleche, Y. Cao, C.Y. Fonseka, G. Wang, E. S. Muise, K.X. Zhang, A. Arazi, G. Keras, Z.J. Li, Y. Qu, M.F. Gurish, M. Petri, J. P. Buyn, C. Putterman, D. Wofsy, J.A. James, J.M. Guthridge, B. Diamond, J. H. Anolik, M.F. Mackey, S.E. Alves, P.A. Nigrovic, K.H. Costenbader, M. B. Brenner, J.A. Lederer, D.A. Rao, PD-1hiCXCR5⁺ T peripheral helper cells promote B cell responses in lupus via MAF and IL-21, *JCI Insight* 4 (2019), e130062, <https://doi.org/10.1172/jci.insight.130062>.
- [44] S.K. Lee, R.J. Rigby, D. Zotos, L.M. Tsai, S. Kawamoto, J.L. Marshall, R. R. Ramiscal, T.D. Chan, D. Gatto, R. Brink, D. Yu, S. Fagarasan, D.M. Tarlinton, A. F. Cunningham, C.G. Vinuesa, B cell priming for extrafollicular antibody responses requires Bcl-6 expression by T cells, *J. Exp. Med.* 208 (2011) 1377–1388, <https://doi.org/10.1084/jem.20102065>.
- [45] D.A. Rao, M.F. Gurish, J.L. Marshall, K. Slowikowski, C.Y. Fonseka, Y. Liu, L. T. Donlin, L.A. Henderson, K. Wei, F. Mizoguchi, N.C. Teslovich, M.E. Weinblatt, E.M. Massarotti, J.S. Cobllyn, S.M. Helfgott, Y.C. Lee, D.J. Todd, V.P. Bykerk, S. M. Goodman, A.B. Pernis, L.B. Ivashkiv, E.W. Karlson, P.A. Nigrovic, A. Filer, C. D. Buckley, J.A. Lederer, S. Raychaudhuri, M.B. Brenner, Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis, *Nature* 542 (2017) 110–114, <https://doi.org/10.1038/nature20810>.
- [46] F. Facciotti, P. Larghi, R. Bosotti, C. Vasco, N. Gagliani, C. Cordiglieri, S. Mazzara, V. Ranzani, E. Rottoli, S. Curti, A. Penatti, B. Karnani, Y. Kobayashi, M. Crosti, M. Bombaci, J.P. van Hamburg, G. Rossetti, R. Gualtierotti, M. Gerosa, S. Gatti, S. Torretta, L. Pignataro, S.W. Tas, S. Abrignani, M. Pagani, F. Grassi, P.L. Meroni, R.A. Flavell, J. Geginat, Evidence for a pathogenic role of extrafollicular, IL-10-producing CCR6⁺B helper T cells in systemic lupus erythematosus, *Proc. Natl. Acad. Sci.* 117 (2020) 7305–7316, <https://doi.org/10.1073/pnas.1917834117>.
- [47] S. Caielli, D.T. Veiga, P. Balasubramanian, S. Athale, B. Domic, E. Murat, R. Banchemareau, Z. Xu, M. Chandra, C.H. Chung, L. Walters, J. Baisch, T. Wright, M. Punaro, L. Nassi, K. Stewart, J. Fuller, D. Ucar, H. Ueno, J. Zhou, J. Banchemareau, V. Pascual, A CD4⁺ T cell population expanded in lupus blood provides B cell help through interleukin-10 and succinate, *Nat. Med.* 25 (2019) 75–81, <https://doi.org/10.1038/s41591-018-0254-9>.
- [48] L. Mesin, J. Ersching, G.D. Victora, Germinal center B cell dynamics, *Immunity* 45 (2016) 471–482, <https://doi.org/10.1016/j.immuni.2016.09.001>.
- [49] C.D.C. Allen, T. Okada, J.G. Cyster, Germinal-center organization and cellular dynamics, *Immunity* 27 (2007) 190–202, <https://doi.org/10.1016/j.immuni.2007.07.009>.
- [50] T. Inoue, R. Shinnakasu, W. Ise, C. Kawai, T. Egawa, T. Kurosaki, The transcription factor Foxo1 controls germinal center B cell proliferation in response to T cell help, *J. Exp. Med.* 214 (2017) 1181–1198, <https://doi.org/10.1084/jem.20161263>.
- [51] G. Cattoretti, M. Büttner, R. Shaknovich, E. Kremmer, B. Alobeid, G. Niedobitek, Nuclear and cytoplasmic AID in extrafollicular and germinal center B cells, *Blood* 107 (2006) 3967–3975, <https://doi.org/10.1182/blood-2005-10-4170>.
- [52] K.M. Spillane, P. Tolar, Mechanics of antigen extraction in the B cell synapse, *Mol. Immunol.* 101 (2018) 319–328, <https://doi.org/10.1016/j.molimm.2018.07.018>.
- [53] K.M. Spillane, P. Tolar, B cell antigen extraction is regulated by physical properties of antigen-presenting cells, *J. Cell Biol.* 216 (2016) 217–230, <https://doi.org/10.1083/jcb.201607064>.
- [54] F.D. Batista, D. Iber, M.S. Neuberger, B cells acquire antigen from target cells after synapse formation, *Nature* 411 (2001) 489–494, <https://doi.org/10.1038/35078099>.
- [55] J.M.J. Tas, L. Mesin, G. Pasqual, S. Targ, J.T. Jacobsen, Y.M. Mano, C.S. Chen, J. C. Weill, C.A. Reynaud, E.P. Browne, M. Meyer-Hermann, G.D. Victora, Visualizing antibody affinity maturation in germinal centers, *Science* 351 (2016) 1048–1054, <https://doi.org/10.1126/science.1243439>.
- [56] N.J. Kräutler, D. Suan, D. Butt, K. Bourne, J.R. Hermes, T.D. Chan, C. Sundling, W. Kaplan, P. Schofield, J. Jackson, A. Basten, D. Christ, R. Brink, Differentiation of germinal center B cells into plasma cells is initiated by high-affinity antigen and completed by Tfh cells, *J. Exp. Med.* 214 (2017) 1259–1267, <https://doi.org/10.1084/jem.20161533>.
- [57] W. Ise, K. Fujii, K. Shiroguchi, A. Ito, K. Kometani, K. Takeda, E. Kawakami, K. Yamashita, K. Suzuki, T. Okada, T. Kurosaki, T follicular helper cell-germinal center B cell interaction strength regulates entry into plasma cell or recycling germinal center cell fate, *Immunity* 48 (2018) 702–715, <https://doi.org/10.1016/j.immuni.2018.03.027>, e4.
- [58] F.J. Weisel, G.V. Zuccarino-Catania, M. Chikina, M.J. Shlomchik, A temporal switch in the germinal center determines differential output of memory B and plasma cells, *Immunity* 44 (2016) 116–130, <https://doi.org/10.1016/j.immuni.2015.12.004>.
- [59] C. Viant, T. Wirthmiller, M.A. ElTanbouly, S.T. Chen, M. Cipolla, V. Ramos, T. Y. Oliveira, L. Stamatatos, M.C. Nussenzweig, Germinal center-dependent and -independent memory B cells produced throughout the immune response, *J. Exp. Med.* 218 (2021), e20202489, <https://doi.org/10.1084/jem.20202489>.
- [60] D. Paus, T.G. Phan, T.D. Chan, S. Gardam, A. Basten, R. Brink, Antigen recognition strength regulates the choice between extrafollicular plasma cell and germinal center B cell differentiation, *J. Exp. Med.* 203 (2006) 1081–1091, <https://doi.org/10.1084/jem.20060087>.
- [61] A. Floreani, V. Baldo, M. Cristofolletti, G. Renzulli, A. Valeri, C. Zanetti, R. Trivello, Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers, *Vaccine* 22 (2004) 607–610, <https://doi.org/10.1016/j.vaccine.2003.09.001>.
- [62] M.K. Slifka, M. Matloubian, R. Ahmed, Bone marrow is a major site of long-term antibody production after acute viral infection, *J. Virol.* 69 (1995) 1895–1902, <https://doi.org/10.1128/jvi.69.3.1895-1902.1995>.
- [63] I.J. Amanna, N.E. Carlson, M.K. Slifka, Duration of humoral immunity to common viral and vaccine antigens, *N. Engl. J. Med.* 357 (2007) 1903–1915, <https://doi.org/10.1056/NEJMoa066092>.
- [64] B.P. O'Connor, M. Cascalho, R.J. Noelle, Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population, *J. Exp. Med.* 195 (2002) 737–745, <https://doi.org/10.1084/jem.20011626>.
- [65] M.K. Slifka, R. Antia, J.K. Whitmire, R. Ahmed, Humoral immunity due to long-lived plasma cells, *Immunity* 8 (1998) 363–372, [https://doi.org/10.1016/S1074-7613\(00\)80541-5](https://doi.org/10.1016/S1074-7613(00)80541-5).
- [66] C.W. Davis, K.J.L. Jackson, M.M. McCausland, J. Darce, C. Chang, S. L. Linderman, C. Chennareddy, R. Gerkin, S.J. Brown, J. Wrammert, A.K. Mehta, W.C. Cheung, S.D. Boyd, E.K. Waller, R. Ahmed, Influenza vaccine-induced human bone marrow plasma cells decline within a year after vaccination, *Science* 370 (2020) 237–241, <https://doi.org/10.1126/science.aaz8432>.
- [67] D.L. Burnett, D.B. Langley, P. Schofield, J.R. Hermes, T.D. Chan, J. Jackson, K. Bourne, J.H. Reed, K. Patterson, B.T. Porebski, R. Brink, D. Christ, C. C. Goodnow, Germinal center antibody mutation trajectories are determined by rapid self/foreign discrimination, *Science* 360 (2018) 223–226, <https://doi.org/10.1126/science.aao3859>.
- [68] J. Steen, B. Forsström, P. Sahlström, V. Odowd, L. Israelsson, A. Krishnamurthy, S. Badreh, L. Mathsson Alm, J. Compson, D. Ramsköld, W. Ndlovu, S. Rapecki, M. Hansson, P.J. Titcombe, H. Bang, D.L. Mueller, A.I. Catrina, C. Grönwall, K. Skriner, P. Nilsson, D. Lightwood, L. Klareskog, V. Malmström, Recognition of amino acid motifs, rather than specific proteins, by human plasma cell-derived monoclonal antibodies to posttranslationally modified proteins in rheumatoid arthritis, *Arthritis Rheumatol.* 71 (2019) 196–209, <https://doi.org/10.1002/art.40699>.
- [69] B. Mietzner, M. Tsuiji, J. Scheid, K. Velinon, T. Tiller, K. Abraham, J.B. Gonzalez, V. Pascual, D. Stichweh, H. Wardemann, M.C. Nussenzweig, Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors, *Proc. Natl. Acad. Sci.* 105 (2008) 9727–9732, <https://doi.org/10.1073/pnas.0803644105>.
- [70] C. Richardson, A.S. Chida, D. Adlowitz, L. Silver, E. Fox, S.A. Jenks, E. Palmer, Y. Wang, J. Heimburg-Molinario, Q.Z. Li, C. Mohan, R. Cummings, C. Tipton, I. Sanz, Molecular basis of 9G4 B cell autoreactivity in human systemic lupus erythematosus, *J. Immunol.* 191 (2013) 4926–4939, <https://doi.org/10.4049/jimmunol.1202263>.
- [71] A. Cappione, J.H. Anolik, A. Pugh-Bernard, J. Barnard, P. Dutcher, G. Silverman, I. Sanz, Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus, *J. Clin. Invest.* 115 (2005) 3205–3216, <https://doi.org/10.1172/JCI24179>.
- [72] L. Le Pottier, V. Devauchelle, A. Fautrel, C. Daridon, A. Saraux, P. Youinou, J. O. Pers, Ectopic germinal centers are rare in Sjögren's syndrome salivary glands and do not exclude autoreactive B cells, *J. Immunol.* 182 (2009) 3540–3547, <https://doi.org/10.4049/jimmunol.0803588>.
- [73] M.A. Linterman, W. Pierson, S.K. Lee, A. Kallies, S. Kawamoto, T.F. Rayner, M. Srivastava, D.P. Divekar, L. Beaton, J.J. Hogan, S. Fagarasan, A. Liston, K.G. C. Smith, C.G. Vinuesa, Foxp3⁺ follicular regulatory T cells control the germinal center response, *Nat. Med.* 17 (2011) 975–982, <https://doi.org/10.1038/nm.2425>.
- [74] B. Riboutout, M. Zandecki, Plasma cell morphology in multiple myeloma and related disorders, *Morphologie* 99 (2015) 38–62, <https://doi.org/10.1016/j.morpho.2015.02.001>.
- [75] C.J. Joyner, A.M. Ley, D.C. Nguyen, M. Ali, A. Corrado, C. Tipton, C.D. Scharer, T. Mi, M.C. Woodruff, J. Hom, J.M. Boss, M. Duan, G. Gibson, D. Roberts, J. Andrews, S. Lonia, I. Sanz, F.E.-H. Lee, Generation of human long-lived plasma cells by developmentally regulated epigenetic imprinting, *Life Sci. Alliance* 5 (2022), e202101285, <https://doi.org/10.26508/lsa.202101285>.
- [76] W. Ise, T. Kurosaki, Plasma cell differentiation during the germinal center reaction, *Immunol. Rev.* 288 (2019) 64–74, <https://doi.org/10.1111/immr.12751>.
- [77] K. Igarashi, K. Ochiai, A. Itoh-Nakadai, A. Muto, Orchestration of plasma cell differentiation by Bach2 and its gene regulatory network, *Immunol. Rev.* 261 (2014) 116–125, <https://doi.org/10.1111/immr.12201>.
- [78] C.D. Scharer, D.G. Patterson, T. Mi, M.J. Price, S.L. Hicks, J.M. Boss, Antibody-secreting cell destiny emerges during the initial stages of B-cell activation, *Nat. Commun.* 11 (2020) 3989, <https://doi.org/10.1038/s41467-020-17798-x>.
- [79] J. Tellier, S.L. Nutt, Plasma cells: the programming of an antibody-secreting machine, *Eur. J. Immunol.* 49 (2019) 30–37, <https://doi.org/10.1002/eji.201847517>.
- [80] W. Schuh, D. Mielenz, H.M. Jäck, Unraveling the mysteries of plasma cells. *Adv. Immunol.* Elsevier, 2020, pp. 57–107, <https://doi.org/10.1016/b.sai.2020.01.002>.
- [81] D. Ricci, T. Gidalevitz, Y. Argon, The special unfolded protein response in plasma cells, *Immunol. Rev.* 303 (2021) 35–51, <https://doi.org/10.1111/immr.13012>.
- [82] M.S.Y. Low, E.J. Brodie, P.L. Fedele, Y. Liao, G. Grigoriadis, A. Strasser, A. Kallies, S.N. Willis, J. Tellier, W. Shi, S. Gabriel, K. O'Donnell, C. Pitt, S.L. Nutt, D. Tarlinton, IRF4 activity is required in established plasma cells to regulate gene transcription and mitochondrial homeostasis, *Cell Rep.* 29 (2019) 2634–2645, <https://doi.org/10.1016/j.celrep.2019.10.097>, e5.
- [83] N. Taubenheim, D.M. Tarlinton, S. Crawford, L.M. Corcoran, P.D. Hodgkin, S. L. Nutt, High rate of antibody secretion is not integral to plasma cell differentiation as revealed by XBP-1 deficiency, *J. Immunol.* 189 (2012) 3328–3338, <https://doi.org/10.4049/jimmunol.1201042>.
- [84] J. Tellier, W. Shi, M. Minnich, Y. Liao, S. Crawford, G.K. Smyth, A. Kallies, M. Busslinger, S.L. Nutt, Blimp-1 controls plasma cell function through the

- regulation of immunoglobulin secretion and the unfolded protein response, *Nat. Immunol.* 17 (2016) 323–330, <https://doi.org/10.1038/ni.3348>.
- [85] E. Bromage, R. Stephens, L. Hassoun, The third dimension of ELISPOts: quantifying antibody secretion from individual plasma cells, *J. Immunol. Methods* 346 (2009) 75–79, <https://doi.org/10.1016/j.jim.2009.05.005>.
- [86] J. Mestecky, M.W. Russell, S. Jackson, T.A. Brown, The human IgA system: a reassessment, *Clin. Immunol. Immunopathol.* 40 (1986) 105–114, [https://doi.org/10.1016/0090-1229\(86\)90073-5](https://doi.org/10.1016/0090-1229(86)90073-5).
- [87] F.G. Kroese, W.H. Abdulhad, E. Haacke, N.A. Bos, A. Vissink, H. Bootsma, B-cell hyperactivity in primary Sjögren's syndrome, *Expert Rev. Clin. Immunol.* 10 (2014) 483–499, <https://doi.org/10.1586/1744666X.2014.891439>.
- [88] N.M. van Leeuwen, M. Boonstra, J.A. Bakker, A. Grummels, S. Jordan, S. Liem, O. Distler, A.M. Hoffmann-Vold, K. Melsens, V. Smith, M.E. Truchetet, H. U. Scherer, R. Toes, T.W.J. Huizinga, J.K. de Vries-Bouwstra, Anticentromere antibody levels and isotypes and the development of systemic sclerosis, *Arthritis Rheumatol.* 73 (2021) 2338–2347, <https://doi.org/10.1002/art.41814>.
- [89] A. Bakri Hassan, J. Rönnelid, I. Gunnarsson, G. Karlsson, L. Berg, I. Lundberg, Increased serum levels of immunoglobulins, C-reactive protein, type 1 and type 2 cytokines in patients with mixed connective tissue disease, *J. Autoimmun.* 11 (1998) 503–508, <https://doi.org/10.1006/jaut.1998.0236>.
- [90] R. McMillan, R.L. Longmire, R. Yelenoski, J.E. Lang, V. Heath, C.G. Craddock, Immunoglobulin synthesis by human lymphoid tissues: normal bone marrow as a major site of IgG production, *J. Immunol. Baltim. Md* 109 (1972) (1950) 1386–1394.
- [91] B.F. Hoyer, K. Moser, A.E. Hauser, A. Peddinghaus, C. Voigt, D. Eilat, A. Radbruch, F. Hiepe, R.A. Manz, Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice, *J. Exp. Med.* 199 (2004) 1577–1584, <https://doi.org/10.1084/jem.20040168>.
- [92] H.Y. Huang, A. Rivas-Caicedo, F. Renevey, H. Cannelle, E. Peranzoni, L. Scarpellino, D.L. Hardie, A. Pommier, K. Schaeuble, S. Favre, T.K. Vogt, F. Arenzana-Seisdedos, P. Schneider, C.D. Buckley, E. Donnadieu, S.A. Luther, Identification of a new subset of lymph node stromal cells involved in regulating plasma cell homeostasis, *Proc. Natl. Acad. Sci.* 115 (2018) E6826–E6835, <https://doi.org/10.1073/pnas.1712628115>.
- [93] M. Odendahl, A. Jacobi, A. Hansen, E. Feist, F. Hiepe, G.R. Burmester, P.E. Lipsky, A. Radbruch, T. Dörner, Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus, *J. Immunol.* 165 (2000) 5970–5979, <https://doi.org/10.4049/jimmunol.165.10.5970>.
- [94] K. Ma, J. Li, X. Wang, X. Lin, W. Du, X. Yang, F. Mou, Y. Fang, Y. Zhao, X. Hong, K.W. Chan, X. Zhang, D. Liu, L. Sun, L. Lu, TLR4+CXCR4+ plasma cells drive nephritis development in systemic lupus erythematosus, *Ann. Rheum. Dis.* 77 (2018) 1498–1506, <https://doi.org/10.1136/annrheumdis-2018-213615>.
- [95] E.A. Szyszko, J.G. Brun, K. Skarstein, A.B. Peck, R. Jonsson, K.A. Brokstad, Phenotypic diversity of peripheral blood plasma cells in primary Sjögren's syndrome: phenotypic diversity of plasma cells in pSS, *Scand. J. Immunol.* 73 (2011) 18–28, <https://doi.org/10.1111/j.1365-3083.2010.02475.x>.
- [96] E.A. Szyszko, K.A. Brokstad, G. Ojordsbakken, M.V. Jonsson, R. Jonsson, K. Skarstein, Salivary glands of primary Sjögren's syndrome patients express factors vital for plasma cell survival, *Arthritis Res. Ther.* 13 (2011) R2, <https://doi.org/10.1186/ar3220>.
- [97] I. Arroyo-Villa, M.B. Bautista-Caro, A. Balsa, P. Aguado-Acín, M.G. Bonilla-Hernán, C. Plasencia, A. Villalba, L. Nuño, A. Puig-Kröger, E. Martín-Mola, M. E. Miranda-Carús, Constitutively altered frequencies of circulating follicular helper T cell counterparts and their subsets in rheumatoid arthritis, *Arthritis Res. Ther.* 16 (2014) 500, <https://doi.org/10.1186/s13075-014-0500-6>.
- [98] S. Bosello, C. Angelucci, G. Lama, S. Alivernini, G. Proietti, B. Tolusso, G. Sica, E. Gremese, G. Ferraccioli, Characterization of inflammatory cell infiltrate of scleroderma skin: b cells and skin score progression, *Arthritis Res. Ther.* 20 (2018) 75, <https://doi.org/10.1186/s13075-018-1569-0>.
- [99] P. Shen, S. Fillatreau, Antibody-independent functions of B cells: a focus on cytokines, *Nat. Rev. Immunol.* 15 (2015) 441–451, <https://doi.org/10.1038/nri3857>.
- [100] A.C. Lino, V.D. Dang, V. Lampropoulou, A. Welle, J. Joedicke, J. Pohar, Q. Simon, J. Thalmens, A. Baures, V. Flüher, I. Sakwa, U. Stervbo, S. Ries, L. Jouneau, P. Boudinot, T. Tsubata, T. Adachi, A. Hutloff, T. Dörner, U. Zimmer-Strobl, A. F. de Vos, K. Dahlke, G. Loh, S. Korniots, C. Goosmann, J.C. Weill, C.A. Reynaud, S.H.E. Kaufmann, J. Walter, S. Fillatreau, LAG-3 Inhibitory Receptor Expression Identifies Immunosuppressive Natural Regulatory Plasma Cells, 49, *Immunity*, 2018, pp. 120–133, <https://doi.org/10.1016/j.immuni.2018.06.007>, e9.
- [101] P. Shen, T. Roch, V. Lampropoulou, R.A. O'Connor, U. Stervbo, E. Hilgenberg, S. Ries, V.D. Dang, Y. Jaimes, C. Daridon, R. Li, L. Jouneau, P. Boudinot, S. Wilantri, I. Sakwa, Y. Miyazaki, M.D. Leech, R.C. McPherson, S. Wirtz, M. Neurath, K. Hoehlig, E. Meinel, A. Grützkau, J.R. Grün, K. Horn, A.A. Kühl, T. Dörner, A. Bar-Or, S.H.E. Kaufmann, S.M. Anderson, S. Fillatreau, IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases, *Nature* 507 (2014) 366–370, <https://doi.org/10.1038/nature12979>.
- [102] M. Matsumoto, A. Baba, T. Yokota, H. Nishikawa, Y. Ohkawa, H. Kayama, A. Kallies, S.L. Nutt, S. Sakaguchi, K. Takeda, T. Kurosaki, Y. Baba, Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation, *Immunity* 41 (2014) 1040–1051, <https://doi.org/10.1016/j.immuni.2014.10.016>.
- [103] A. de Masson, J.D. Bouaziz, H. Le Buanec, M. Robin, A. O'Meara, N. Parquet, M. Rybojad, E. Hau, J.B. Monfort, M. Branchtein, D. Michonneau, V. Dessirier, F. Sicre de Fontbrune, A. Bergeron, R. Itzykson, N. Dhédin, D. Bengoufa, R. Peffault de Latour, A. Xhaard, M. Bagot, A. Bensussan, G. Socié, CD24hiCD27+
- and plasmablast-like regulatory B cells in human chronic graft-versus-host disease, *Blood* 125 (2015) 1830–1839, <https://doi.org/10.1182/blood-2014-09-599159>.
- [104] D.A. Bermejo, S.W. Jackson, M. Gorosito-Serran, E.V. Acosta-Rodriguez, M. C. Amezcua-Vesely, B.D. Sather, A.K. Singh, S. Khim, J. Mucci, D. Liggett, O. Campetella, M. Oukka, A. Gruppi, D.J. Rawlings, Trypanosoma cruzi trans-sialidase initiates a program independent of the transcription factors ROR γ t and Ahr that leads to IL-17 production by activated B cells, *Nat. Immunol.* 14 (2013) 514–522, <https://doi.org/10.1038/ni.2569>.
- [105] P.J. Rauch, A. Chudnovskiy, C.S. Robbins, G.F. Weber, M. Eitzrodt, I. Hilgendorf, E. Tiglaio, J.L. Figueiredo, Y. Iwamoto, I. Theurl, R. Gorbатов, M.T. Waring, A. T. Chicoine, M. Mouded, M.J. Pittet, M. Nahrens, R. Weissleder, F.K. Swirski, Innate response activator B cells protect against microbial sepsis, *Science* 335 (2012) 597–601, <https://doi.org/10.1126/science.1215173>.
- [106] R.A. Manz, A. Radbruch, Plasma cells for a lifetime? *Eur. J. Immunol.* 32 (2002) 923–927, [https://doi.org/10.1002/1521-4141\(200204\)32:4<923::AID-IMMU923>3.0.CO;2-1](https://doi.org/10.1002/1521-4141(200204)32:4<923::AID-IMMU923>3.0.CO;2-1).
- [107] F. Medina, C. Segundo, A. Campos-Caro, I. González-García, J.A. Brieua, The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression, *Blood* 99 (2002) 2154–2161, <https://doi.org/10.1182/blood.V99.6.2154>.
- [108] M. Odendahl, H. Mei, B.F. Hoyer, A.M. Jacobi, A. Hansen, G. Muehlinghaus, C. Berek, F. Hiepe, R. Manz, A. Radbruch, T. Dörner, Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response, *Blood* 105 (2005) 1614–1621, <https://doi.org/10.1182/blood-2004-07-2507>.
- [109] H.E. Mei, I. Wirries, D. Frölich, M. Brissler, C. Giesecke, J.R. Grün, T. Alexander, S. Schmidt, K. Luda, A.A. Kühl, R. Engelmann, M. Dürr, T. Scheel, M. Bokarewa, C. Perka, A. Radbruch, T. Dörner, A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow, *Blood* 125 (2015) 1739–1748, <https://doi.org/10.1182/blood-2014-02-555169>.
- [110] A. Caraux, B. Klein, B. Paiva, C. Bret, A. Schmitz, G.M. Fuhler, N.A. Bos, H. E. Johnsen, A. Orfao, M. Perez-Andres, for the M.S.C. Network (MSCNET), Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138⁺ and CD138⁺ plasma cells, *Haematologica* 95 (2010) 1016–1020, <https://doi.org/10.3324/haematol.2009.018689>.
- [111] K. Pracht, J. Meinzinger, P. Daum, S.R. Schulz, D. Reimer, M. Hauke, E. Roth, D. Mielenz, C. Berek, J. Córte-Real, H.M. Jäck, W. Schuh, A new staining protocol for detection of murine antibody-secreting plasma cell subsets by flow cytometry, *Eur. J. Immunol.* 47 (2017) 1389–1392, <https://doi.org/10.1002/eji.201747019>.
- [112] A. Cossarizza, H. Chang, A. Radbruch, A. Acs, D. Adam, S. Adam-Klages, W. W. Agace, N. Aghaepour, M. Akdis, M. Allez, L.N. Almeida, G. Alvisi, G. Anderson, I. André, F. Annunziato, A. Anselmo, P. Bacher, C.T. Baldari, S. Bari, V. Barnaba, L. Battistini, W. Bauer, S. Baumgart, N. Baumgarth, D. Baumjohann, B. Baying, M. Bewawy, B. Becher, W. Beisker, V. Benes, R. Beyaert, A. Blanco, D. A. Boardman, C. Bogdan, J.G. Borger, G. Borsellino, P.E. Boulais, J.A. Bradford, D. Brenner, R.R. Brinkman, A.E.S. Brooks, D.H. Busch, M. Büscher, T.P. Bushnell, F. Calzetti, G. Cameron, I. Cammarata, X. Cao, S.L. Cardell, S. Casola, M. A. Casatella, A. Cavani, A. Celada, L. Chatenoud, P.K. Chattopadhyay, S. Chow, E. Christakou, L. Čičin-Šain, M. Clerici, F.S. Colombo, L. Cook, A. Cooke, A. M. Cooper, A.J. Corbett, A. Cosma, L. Cosmi, P.G. Coulie, A. Cumano, L. Cvetkovic, V.D. Dang, C. Dang-Heine, M.S. Davey, D. Davies, S. De Biasi, G. Del Zotto, G.V. Dela Cruz, M. Delacher, S. Della Bella, P. Dellabona, G. Deniz, M. Dessing, J.P. Di Santo, A. Diefenbach, F. Dieli, A. Dolf, T. Dörner, R.J. Dress, M. Dudziak, M. Dustin, C. Dutertre, F. Ebner, S.B.G. Eckle, M. Edinger, P. Eede, G. R.A. Ehrhardt, M. Eich, P. Engel, B. Engelhardt, A. Erdei, C. Esser, B. Everts, M. Evrard, C.S. Falk, T.A. Fehniger, M. Felipe-Benavent, H. Ferry, M. Feuerer, A. Filby, K. Filkor, S. Fillatreau, M. Follo, I. Förster, J. Foster, G.A. Foulds, B. Frehse, P.S. Frenette, S. Frischbuter, W. Fritzsche, D.W. Galbraith, A. Gangaev, N. Garbi, B. Gaudilliere, R.T. Gazzinelli, J. Geginat, W. Gerner, N.A. Gherardin, K. Ghoreschi, L. Gibellini, F. Ginhoux, K. Goda, D.J. Godfrey, C. Goettlinger, J. M. González-Navajas, C.S. Goodyear, A. Gori, J.L. Grogan, D. Grummitt, A. Grützkau, C. Haftmann, J. Hahn, H. Hammad, G. Hämmerling, L. Hansmann, G. Hansson, C.M. Harpur, S. Hartmann, A. Hauser, A.E. Hauser, D.L. Haviland, D. Hedley, D.C. Hernández, G. Herrera, M. Herrmann, C. Hess, T. Höfer, P. Hoffmann, K. Hogquist, T. Holland, T. Höllt, R. Holmdahl, P. Hombrink, J. P. Houston, B.F. Hoyer, B. Huang, F. Huang, J.E. Huber, J. Huehn, M. Hundemer, C.A. Hunter, W.Y.K. Hwang, A. Iannone, F. Ingelfinger, S.M. Ivison, H. Jäck, P. K. Jani, B. Jávega, S. Jonjic, T. Kaiser, T. Kalina, T. Kamradt, S.H.E. Kaufmann, B. Keller, S.L.C. Ketelaars, A. Khalilzadeh, S. Khan, J. Kisielov, P. Klenerman, J. Knopf, H. Koay, K. Kobow, J.K. Kolls, W.T. Kong, M. Kopf, T. Korn, K. Kriegsmann, H. Kristyanto, T. Kronska, A. Krueger, J. Kühne, C. Kukat, D. Kunkel, H. Kunze-Schumacher, T. Kurosaki, C. Kurts, P. Kvistborg, I. Kwok, J. Landry, O. Lantz, P. Lanuti, F. LaRosa, A. Lehen, S. LeibundGut-Landmann, M. D. Leibold, L.Y.T. Leung, M.K. Levings, A.C. Lino, F. Liotta, V. Litwin, Y. Liu, H. Ljunggren, M. Lohoff, G. Lombardi, L. Lopez, M. López-Botet, A.E. Lovett-Racke, E. Lubbers, H. Luche, B. Ludewig, E. Lugli, S. Lunemann, H.T. Maecker, L. Maggi, O. Maguire, F. Mair, K.H. Mair, A. Mantovani, R.A. Manz, A.J. Marshall, A. Martínez-Romero, G. Martus, I. Marventano, W. Maslinski, G. Matarese, A. V. Mattioli, C. Maueröder, A. Mazzoni, J. McCluskey, M. McGrath, H.M. McGuire, I.B. McInnes, H.E. Mei, F. Melchers, S. Melzer, D. Mielenz, S.D. Miller, K.H. G. Mills, H. Minderman, J. Mjöberg, J. Moore, B. Moran, L. Moretta, T. R. Mosmann, S. Müller, G. Multhoff, L.E. Muñoz, C. Münz, T. Nakayama, M. Nasi, K. Neumann, L.G. Ng, A. Niedobitek, S. Nourshargh, G. Núñez, J. O'Connor,

- A. Ochel, A. Oja, D. Ordonez, A. Orfao, E. Orlowski-Oliver, W. Ouyang, A. Oxenius, R. Palankar, I. Panse, K. Pattanapanyasat, M. Paulsen, D. Pavlinic, L. Penter, P. Peterson, C. Peth, J. Petriz, F. Piancone, W.F. Pickl, S. Piconese, M. Pinti, A.G. Pockley, M.J. Podolska, Z. Poon, K. Pracht, I. Prinz, C.E.M. Pucillo, S.A. Quataert, L. Quatrini, K.M. Quinn, H. Radbruch, T.R.D.J. Radstake, S. Rahmig, H. Rahn, B. Rajwa, G. Ravichandran, Y. Raz, J.A. Rebhahn, D. Recktenwald, D. Reimer, C. Reis e Sousa, E.B.M. Remmerswaal, L. Richter, L. G. Rico, A. Riddell, A.M. Rieger, J.P. Robinson, C. Romagnani, A. Rubartelli, J. Ruland, A. Saalmüller, Y. Saeyes, T. Saito, S. Sakaguchi, F. Sala-de-Oyanguen, Y. Samstag, S. Sanderson, I. Sandrock, A. Santoni, R.B. Sanz, M. Saresella, C. Sautes-Fridman, B. Sawitzki, L. Schadt, A. Scheffold, H.U. Scherer, M. Schiemann, F.A. Schildberg, E. Schimisky, A. Schlitzer, J. Schlosser, S. Schmid, S. Schmitt, K. Schober, D. Schraivogel, W. Schuh, T. Schüler, R. Schulte, A. R. Schulz, S.R. Schulz, C. Scott, D. Scott-Algara, D.P. Sester, T.V. Shankey, B. Silva-Santos, A.K. Simon, K.M. Sitnik, S. Sozzani, D.E. Speiser, J. Spidlen, A. Stahlberg, A.M. Stall, N. Stanley, R. Stark, C. Stehle, T. Steinmetz, H. Stockinger, Y. Takahama, K. Takeda, L. Tan, A. Tárnok, G. Tiegs, G. Toldi, J. Tornack, E. Traggiai, M. Trebak, T.I.M. Tree, J. Trotter, J. Trowsdale, M. Tsoumakidou, H. Ulrich, S. Urbanczyk, W. Veen, M. Broek, E. Pol, S. Van Gassen, G. Van Isterdael, R.A.W. Lier, M. Veldhoen, S. Vento-Asturias, P. Vieira, D. Voehringer, H. Volk, A. Borstel, K. Volkman, A. Waisman, R.V. Walker, P. K. Wallace, S.A. Wang, X.M. Wang, M.D. Ward, K.A. Ward-Hartstonge, K. Warnatz, G. Warnes, S. Warth, C. Waskow, J.V. Watson, C. Watzl, L. Wegener, T. Weisenburger, A. Wiedemann, J. Wienands, A. Wilharm, R.J. Wilkinson, G. Willmisky, J.B. Wing, R. Winkelmann, T.H. Winkler, O.F. Wirz, A. Wong, P. Wurst, J.H.M. Yang, J. Yang, M. Yazdanbakhsh, L. Yu, A. Yue, H. Zhang, Y. Zhao, S.M. Ziegler, C. Zielinski, J. Zimmermann, A. Zychlinsky, Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition), *Eur. J. Immunol.* 49 (2019) 1457–1973, <https://doi.org/10.1002/eji.201970107>.
- [113] M.J. McCarron, P.W. Park, D.R. Fooksman, CD138 mediates selection of mature plasma cells by regulating their survival, *Blood* 129 (2017) 2749–2759, <https://doi.org/10.1182/blood-2017-01-761643>.
- [114] R. Gharbaran, Advances in the molecular functions of syndecan-1 (SDC1/CD138) in the pathogenesis of malignancies, *Crit. Rev. Oncol. Hematol.* 94 (2015) 1–17, <https://doi.org/10.1016/j.critrevonc.2014.12.003>.
- [115] J.L. Halliley, C.M. Tipton, J. Liesveld, A.F. Rosenberg, J. Darce, I.V. Gregoret, L. Popova, D. Kaminiski, C.F. Fucile, I. Albizua, S. Kyu, K.Y. Chiang, K.T. Bradley, R. Burack, M. Slifka, E. Hammarlund, H. Wu, L. Zhao, E.E. Walsh, A.R. Falsey, T. D. Randall, W.C. Cheung, I. Sanz, F.E.-H. Lee, Long-lived plasma cells are contained within the CD19–CD38hiCD138+ subset in human bone marrow, *Immunity* 43 (2015) 132–145, <https://doi.org/10.1016/j.immuni.2015.06.016>.
- [116] S.F. Brynjolfsson, M. Mohaddes, J. Kärrholm, M.J. Wick, Long-lived plasma cells in human bone marrow can be either CD19+ or CD19–, *Blood Adv.* 1 (2017) 835–838, <https://doi.org/10.1182/bloodadvances.2017004481>.
- [117] S.S. Mujtahedi, F. Yigitbilek, Y. Benavides, M.A. Merzkanli, E. Ozdogan, O. Abozied, N.A. Moore, W.D. Park, M.D. Stegall, Bone marrow derived long-lived plasma cell phenotypes are heterogeneous and can change in culture, *Transpl. Immunol.* (2022), 101726, <https://doi.org/10.1016/j.trim.2022.101726>.
- [118] S. Garimalla, D.C. Nguyen, J.L. Halliley, C. Tipton, A.F. Rosenberg, C.F. Fucile, C. L. Lane, S. Kyu, D. Kaminiski, Y. Qian, R.H. Scheuermann, G. Gibson, I. Sanz, F. E.-H. Lee, Differential transcriptome and development of human peripheral plasma cell subsets, *JCI Insight* 4 (2019), <https://doi.org/10.1172/jci.insight.126732>.
- [119] T.D. Steinmetz, G.M. Verstappen, S.R. Schulz, L. de Wolff, R. Wilbrink, A. Visser, J. Terpstra, H. Bootsma, F.G.M. Kroese, Maturity of circulating antibody-secreting cells is associated with disease features in primary Sjögren's syndrome, *Arthritis Rheumatol.* (2022) 42422, <https://doi.org/10.1002/art.42422>, art.
- [120] M. Cocco, S. Stephenson, M.A. Care, D. Newton, N.A. Barnes, A. Davison, A. Rawstron, D.R. Westhead, G.M. Doody, R.M. Toozie, In vitro generation of long-lived human plasma cells, *J. Immunol.* (2012), <https://doi.org/10.4049/jimmunol.1103720>.
- [121] R. Cornelis, S. Hahne, A. Taddeo, G. Petkau, D. Malko, P. Durek, M. Thiem, L. Heiberger, L. Peter, E. Mohr, C. Klaeden, K. Tokoyoda, F. Siracusa, B.F. Hoyer, F. Hiepe, M.F. Mashreghi, F. Melchers, H.D. Chang, A. Radbruch, Stromal cell-contact dependent PI3K and APRIL induced NF- κ B signaling prevent mitochondrial- and ER stress induced death of memory plasma cells, *Cell Rep.* 32 (2020), 107982, <https://doi.org/10.1016/j.celrep.2020.107982>.
- [122] D.C. Nguyen, S. Garimalla, H. Xiao, S. Kyu, I. Albizua, J. Galipeau, K.Y. Chiang, E. K. Waller, R. Wu, G. Gibson, J. Roberson, F.E. Lund, T.D. Randall, I. Sanz, F.E.-H. Lee, Factors of the bone marrow microenvironment that support human plasma cell survival and immunoglobulin secretion, *Nat. Commun.* 9 (2018) 3698, <https://doi.org/10.1038/s41467-018-05853-7>.
- [123] F. Hiepe, A. Radbruch, Plasma cells as an innovative target in autoimmune disease with renal manifestations, *Nat. Rev. Nephrol.* 12 (2016) 232–240, <https://doi.org/10.1038/nrneph.2016.20>.
- [124] H.A.M. Wols, G.H. Underhill, G.S. Kansas, P.L. Witte, The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity, *J. Immunol.* 169 (2002) 4213–4221, <https://doi.org/10.4049/jimmunol.169.8.4213>.
- [125] D.J. DiLillo, Y. Hamaguchi, Y. Ueda, K. Yang, J. Uchida, K.M. Haas, G. Kelsoe, T. F. Tedder, Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice, *J. Immunol.* 180 (2008) 361–371, <https://doi.org/10.4049/jimmunol.180.1.361>.
- [126] C. Männe, A. Takaya, Y. Yamasaki, M. Mursell, S. Hojyo, T.Y. Wu, J. Sarkander, M.A. McGrath, R. Cornelis, S. Hahne, Q. Cheng, T. Kawamoto, F. Hiepe, S.H. E. Kaufmann, T. Yamamoto, A. Radbruch, K. Tokoyoda, Salmonella SiiE prevents an efficient humoral immune memory by interfering with IgG+ plasma cell persistence in the bone marrow, *Proc. Natl. Acad. Sci.* 116 (2019) 7425–7430, <https://doi.org/10.1073/pnas.1818242116>.
- [127] M.R. Gomez, Y. Talke, N. Goebel, F. Hermann, B. Reich, M. Mack, Basophils support the survival of plasma cells in mice, *J. Immunol.* 185 (2010) 7180–7185, <https://doi.org/10.4049/jimmunol.1002319>.
- [128] O. Winter, K. Moser, E. Mohr, D. Zotos, H. Kaminski, M. Szyska, K. Roth, D. M. Wong, C. Dame, D.M. Tarlinton, H. Schulze, I.C.M. MacLennan, R.A. Manz, Megakaryocytes constitute a functional component of a plasma cell niche in the bone marrow, *Blood* 116 (2010) 1867–1875, <https://doi.org/10.1182/blood-2009-12-259457>.
- [129] E. Mohr, K. Serre, R.A. Manz, A.F. Cunningham, M. Khan, D.L. Hardie, R. Bird, I. C.M. MacLennan, Dendritic cells and monocyte/macrophages that create the IL-6/APRIL-rich lymph node microenvironments where plasmablasts mature, *J. Immunol.* 182 (2009) 2113–2123, <https://doi.org/10.4049/jimmunol.0802771>.
- [130] T. Matthes, I. Dunand-Sauthier, M.L. Santiago-Raber, K.H. Krause, O. Donze, J. Passweg, T. McKee, B. Huard, Production of the plasma-cell survival factor a proliferation-inducing ligand (APRIL) peaks in myeloid precursor cells from human bone marrow, *Blood* 118 (2011) 1838–1844, <https://doi.org/10.1182/blood-2011-01-332940>.
- [131] M.J. Benson, S.R. Dillon, E. Castigli, R.S. Geha, S. Xu, K.P. Lam, R.J. Noelle, Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL, *J. Immunol.* 180 (2008) 3655–3659, <https://doi.org/10.4049/jimmunol.180.6.3655>.
- [132] B.P. O'Connor, V.S. Raman, L.D. Erickson, W.J. Cook, L.K. Weaver, C. Ahonen, L. L. Lin, G.T. Mantchev, R.J. Bram, R.J. Noelle, BCMA is essential for the survival of long-lived bone marrow plasma cells, *J. Exp. Med.* 199 (2004) 91–98, <https://doi.org/10.1084/jem.20031330>.
- [133] A. Pascual-Reguant, R. Köhler, R. Mothes, S. Bauherr, D.C. Hernández, R. Uecker, K. Holzwarth, K. Kotsch, M. Seidl, L. Philipsen, W. Müller, C. Romagnani, R. Niesner, A.E. Hauser, Multiplexed histology analyses for the phenotypic and spatial characterization of human innate lymphoid cells, *Nat. Commun.* 12 (2021) 1737, <https://doi.org/10.1038/s41467-021-21994-8>.
- [134] B. Huard, T. McKee, C. Bosshard, S. Durual, T. Matthes, S. Myit, O. Donze, C. Frossard, C. Chizzolini, C. Favre, R. Zubler, J.P. Guyot, P. Schneider, E. Roosnek, APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa, *J. Clin. Invest.* 118 (2008) 2887–2895, <https://doi.org/10.1172/JCI33760>.
- [135] J.M. van Laar, M. Melchers, Y.K.O. Teng, B. van der Zouwen, R. Mohammadi, R. Fischer, L. Margolis, W. Fitzgerald, J.C. Grivel, F.C. Breedveld, P.E. Lipsky, A. C. Grammer, Sustained secretion of immunoglobulin by long-lived human tonsil plasma cells, *Am. J. Pathol.* 171 (2007) 917–927, <https://doi.org/10.2353/ajpath.2007.070005>.
- [136] B. Isho, A. Florescu, A.A. Wang, J.L. Gommerman, Fantastic IgA plasma cells and where to find them, *Immunol. Rev.* 303 (2021) 119–137, <https://doi.org/10.1111/imr.12980>.
- [137] P.M. Speight, A. Cruchley, D.M. Williams, Quantification of plasma cells in labial salivary glands: increased expression of IgM in Sjögren's syndrome, *J. Oral Pathol. Med.* 19 (1990) 126–130, <https://doi.org/10.1111/j.1600-0714.1990.tb00810.x>.
- [138] J. Wittner, S.R. Schulz, T.D. Steinmetz, J. Berges, M. Hauke, W.M. Channell, A. F. Cunningham, A.E. Hauser, A. Hutloff, D. Mielenz, H.M. Jäck, W. Schuh, Krüppel-like factor 2 controls IgA plasma cell compartmentalization and IgA responses, *Mucosal Immunol.* (2022) 1–15, <https://doi.org/10.1038/s41385-022-00503-0>.
- [139] R.P. Wilson, S.E. McGettigan, V.D. Dang, A. Kumar, M.P. Cancro, N. Nikbakht, W. Stohl, G.F. Debes, IgM plasma cells reside in healthy skin and accumulate with chronic inflammation, *J. Invest. Dermatol.* 139 (2019) 2477–2487, <https://doi.org/10.1016/j.jid.2019.05.009>.
- [140] A. Wang, A.M. Fairhurst, K. Tus, S. Subramanian, Y. Liu, F. Lin, P. Igarashi, X. J. Zhou, F. Batteux, D. Wong, E.K. Wakeland, C. Mohan, CXCR4/CXCL12 hyperexpression plays a pivotal role in the pathogenesis of lupus, *J. Immunol.* 182 (2009) 4448–4458, <https://doi.org/10.4049/jimmunol.0801920>.
- [141] U. Hardt, K. Carlberg, E. af Klint, P. Sahlström, L. Larsson, A. van Vollenhoven, S. Hernandez Machado, L. Israelsson, K. Amara, K. Chemin, M. Korotkova, G. B. Karlsson Hedestam, A.I. Catrina, S.A. Teichmann, P.L. Ståhl, V. Malmström, Integrated single cell and spatial transcriptomics reveal autoreactive differentiated B cells in joints of early rheumatoid arthritis, *Sci. Rep.* 12 (2022) 11876, <https://doi.org/10.1038/s41598-022-15293-5>.
- [142] G. Muehlinghaus, L. Cigliano, S. Huehn, A. Peddinghaus, H. Leyendeckers, A. E. Hauser, F. Hiepe, A. Radbruch, S. Arce, R.A. Manz, Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells, *Blood* 105 (2005) 3965–3971, <https://doi.org/10.1182/blood-2004-08-2992>.
- [143] A.E. Hauser, G.F. Debes, S. Arce, G. Cassese, A. Hamann, A. Radbruch, R.A. Manz, Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response, *J. Immunol.* 169 (2002) 1277–1282, <https://doi.org/10.4049/jimmunol.169.3.1277>.
- [144] S. Hosomi, N. Oshitani, N. Kamata, M. Sogawa, H. Okazaki, T. Tanigawa, H. Yamagami, K. Watanabe, K. Tominaga, T. Watanabe, Y. Fujiwara, K. Maeda, K. Hirakawa, T. Arakawa, Increased numbers of immature plasma cells in peripheral blood specifically overexpress chemokine receptor CXCR3 and CXCR4 in patients with ulcerative colitis, *Clin. Exp. Immunol.* 163 (2011) 215–224, <https://doi.org/10.1111/j.1365-2249.2010.04290.x>.

- [145] T. Tsubaki, S. Takegawa, H. Hanamoto, N. Arita, J. Kamogawa, H. Yamamoto, N. Takubo, S. Nakata, K. Yamada, S. Yamamoto, O. Yoshie, M. Nose, Accumulation of plasma cells expressing CXCR3 in the synovial subsiding regions of early rheumatoid arthritis in association with production of Mig/CXCL9 by synovial fibroblasts, *Clin. Exp. Immunol.* 141 (2005) 363–371, <https://doi.org/10.1111/j.1365-2249.2005.02850.x>.
- [146] A. Hutloff, K. Büchner, K. Reiter, H.J. Baelde, M. Odendahl, A. Jacobi, T. Dörner, R.A. Kroczeck, Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus, *Arthritis Rheum.* 50 (2004) 3211–3220, <https://doi.org/10.1002/art.20519>.
- [147] D.E. Jackson, E.T. Lally, M.C. Nakamura, P.C. Montgomery, Migration of IgA-bearing lymphocytes into salivary glands, *Cell. Immunol.* 63 (1981) 203–209, [https://doi.org/10.1016/0008-8749\(81\)90042-3](https://doi.org/10.1016/0008-8749(81)90042-3).
- [148] P. Tengnér, A.K. Halse, H.J. Haga, R. Jonsson, M. Wahren-Herlenius, Detection of anti-Ro/SSA and anti-La/SSB autoantibody-producing cells in salivary glands from patients with Sjögren's syndrome, *Arthritis Rheum.* 41 (1998) 2238–2248, [https://doi.org/10.1002/1529-0131\(199812\)41:12<2238::AID-ART20>3.0.CO;2-V](https://doi.org/10.1002/1529-0131(199812)41:12<2238::AID-ART20>3.0.CO;2-V).
- [149] R.J.U. Kroneld H. Carlsten, T. Bremell, A.C. Johannessen, A. Tarkowski, Expression of the mucosal lymphocyte integrin $\alpha E\beta 7$ and its ligand E-cadherin in salivary glands of patients with Sjögren's syndrome, *Scand. J. Rheumatol.* 27 (1998) 215–218, <https://doi.org/10.1080/030097498440831>.
- [150] P.J. Daniels, C.P. McArthur, D.P. Heruth, P.G. Rothberg, L. Pasztor, Y. Wang, Cytokine-mediated stimulation of laminin expression and cell-growth arrest in a human submandibular gland duct-cell line (HSG), *Arch. Oral Biol.* 44 (1999) 603–615, [https://doi.org/10.1016/S0003-9969\(99\)00024-2](https://doi.org/10.1016/S0003-9969(99)00024-2).
- [151] A.G. Tzioufas, E.K. Kapsogeorgou, H.M. Moutsopoulos, Pathogenesis of Sjögren's syndrome: what we know and what we should learn, *J. Autoimmun.* 39 (2012) 4–8, <https://doi.org/10.1016/j.jaut.2012.01.002>.
- [152] F. Imai, T. Suzuki, T. Ishibashi, M. Tanaka, Y. Akiyama, Y. Dohi, Effect of sulfasalazine on B cell hyperactivity in patients with rheumatoid arthritis, *J. Rheumatol.* 21 (1994) 612–615.
- [153] G. Famularo, R. Giacomelli, E. Alesse, M.G. Cifone, S. Morrone, M. Boirivant, C. Danese, M.A. Perego, A. Santoni, G. Toniatti, Polyclonal B lymphocyte activation in progressive systemic sclerosis, *J. Clin. Lab. Immunol.* 29 (1989) 59–63.
- [154] L.P. Kil, R.W. Hendriks, Aberrant B cell selection and activation in systemic lupus erythematosus, *Int. Rev. Immunol.* 32 (2013) 445–470, <https://doi.org/10.3109/08830185.2013.786712>.
- [155] F.B. Vincent, W.A. Figgitt, M.L. Hibbs, Hallmark of systemic lupus erythematosus: role of B cell hyperactivity, in: A. Hoi (Ed.), *Pathog. Syst. Lupus Erythematosus*, Ed., Springer International Publishing, Cham, 2021, pp. 9–36, https://doi.org/10.1007/978-3-030-85161-3_2.
- [156] J.O. Pers, C. Daridon, V. Devauchelle, S. Jousse, A. Saraux, C. Jamin, P. Youinou, BAFF overexpression is associated with autoantibody production in autoimmune diseases, *Ann. N. Y. Acad. Sci.* 1050 (2005) 34–39, <https://doi.org/10.1196/annals.1313.004>.
- [157] B. Dasgupta, M. Corkill, B. Kirkham, T. Gibson, G. Panayi, Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis, *J. Rheumatol.* 19 (1992) 22–25.
- [158] B. White, Immunopathogenesis of systemic sclerosis, *Rheum. Dis. Clin.* 22 (1996) 695–708, [https://doi.org/10.1016/S0889-857X\(05\)70296-9](https://doi.org/10.1016/S0889-857X(05)70296-9).
- [159] F. Gulli, C. Napodano, M. Marino, G. Ciasca, C. Pocino, V. Basile, M. Visentini, A. Stefanile, L. Todi, M. De Spirito, G.L. Rapaccini, U. Basile, Serum immunoglobulin free light chain levels in systemic autoimmune rheumatic diseases, *Clin. Exp. Immunol.* 199 (2020) 163–171, <https://doi.org/10.1111/cei.13385>.
- [160] A. Lanteri, V. Sobanski, C. Langlois, G. Lefèvre, C. Hauspie, S. Sanges, M. Lambert, S. Morell-Dubois, P.Y. Hatron, E. Hachulla, D. Launay, S. Dubucquoi, Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity, *Autoimmun. Rev.* 13 (2014) 974–980, <https://doi.org/10.1016/j.autrev.2014.07.003>.
- [161] Z. Brkic, L. van Bon, M. Cossu, C.G. van Helden-Meeuwse, M.C. Vonk, H. Knaapen, W. van den Berg, V.A. Dalm, P.L.V. Daele, A. Severino, N.I. Maria, S. Guillen, W.A. Dik, L. Beretta, M.A. Versnel, T. Radstake, The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis, *Ann. Rheum. Dis.* 75 (2016) 1567–1573, <https://doi.org/10.1136/annrheumdis-2015-207392>.
- [162] G.M. Verstappen, S. Pringle, H. Bootsma, F.G.M. Kroese, Epithelial-immune cell interplay in primary Sjögren syndrome salivary gland pathogenesis, *Nat. Rev. Rheumatol.* 17 (2021) 333–348, <https://doi.org/10.1038/s41584-021-00605-2>.
- [163] A.G.A. Kolios, G.C. Tsokos, Skin-kidney crosstalk in SLE, *Nat. Rev. Rheumatol.* 17 (2021) 253–254, <https://doi.org/10.1038/s41584-021-00588-0>.
- [164] C. Mohan, C. Putterman, Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis, *Nat. Rev. Nephrol.* 11 (2015) 329–341, <https://doi.org/10.1038/nrneph.2015.33>.
- [165] P.P. Smith, C. Gordon, Systemic lupus erythematosus: clinical presentations, *Autoimmun. Rev.* 10 (2010) 43–45, <https://doi.org/10.1016/j.autrev.2010.08.016>.
- [166] E. Mossel, M.S. van Ginkel, E.A. Haacke, S. Arends, S.C. Liefers, K. Delli, J.F. van Nimwegen, A.J. Stel, F.K.L. Spijkervet, A. Vissink, B. van der Vegt, F.G.M. Kroese, H. Bootsma, Histopathology, salivary flow and ultrasonography of the parotid gland: three complementary measurements in primary Sjögren's syndrome, *Rheumatology* 61 (2022) 2472–2482, <https://doi.org/10.1093/rheumatology/keab781>.
- [167] M.S. van Ginkel, E.A. Haacke, H. Bootsma, S. Arends, J.F. van Nimwegen, G. M. Verstappen, F.K.L. Spijkervet, A. Vissink, B. van der Vegt, F.G.M. Kroese, Presence of intraepithelial B-lymphocytes is associated with the formation of lymphoepithelial lesions in salivary glands of primary Sjögren's syndrome patients, *Clin. Exp. Rheumatol.* 37 (118) (2019) 42–48. Suppl.
- [168] P. Brito-Zerón, E. Theander, C. Baldini, R. Seror, S. Retamozo, L. Quartuccio, H. Bootsma, S.J. Bowman, T. Dörner, J.E. Gottenberg, X. Mariette, S. Bombardieri, S. de Vita, T. Mandl, W.F. Ng, A.A. Kruize, A. Tzioufas, C. Vitali, J. Buyon, P. Izmirly, R. Fox, M. Ramos-Casals, on behalf of the EULAR Sjögren syndrome task force, early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations, *Expert Rev. Clin. Immunol.* 12 (2016) 137–156, <https://doi.org/10.1586/1744666X.2016.1109449>.
- [169] L. Chatzis, A.V. Goules, V. Pezoulas, C. Baldini, S. Gandolfo, F.N. Skopouli, T. P. Exarchos, E.K. Kapsogeorgou, V. Donati, P.V. Voulgari, C.P. Mavragani, V. Gourgoulis, S. De Vita, D. Fotiadis, M. Voulgarelis, H.M. Moutsopoulos, A. G. Tzioufas, A biomarker for lymphoma development in Sjögren's syndrome: salivary gland focus score, *J. Autoimmun.* 121 (2021), 102648, <https://doi.org/10.1016/j.jaut.2021.102648>.
- [170] R. Seror, G. Nocturne, X. Mariette, Current and future therapies for primary Sjögren syndrome, *Nat. Rev. Rheumatol.* 17 (2021) 475–486, <https://doi.org/10.1038/s41584-021-00634-x>.
- [171] G. Ruiz-Irastorza, G. Bertsias, Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs, *Rheumatology* 59 (2020) v69–v81, <https://doi.org/10.1093/rheumatology/keaa403>.
- [172] G. Yaniv, G. Twig, D.B.-A. Shor, A. Furer, Y. Sherer, O. Mozes, O. Komisar, E. Slonimsky, E. Klang, E. Lotan, M. Welt, I. Marai, A. Shina, H. Amital, Y. Shoenfeld, A volcanic explosion of autoantibodies in systemic lupus erythematosus: a diversity of 180 different autoantibodies found in SLE patients, *Autoimmun. Rev.* 14 (2015) 75–79, <https://doi.org/10.1016/j.autrev.2014.10.003>.
- [173] V.K. Bournia, P.G. Vlachoyiannopoulos, Subgroups of Sjögren syndrome patients according to serological profiles, *J. Autoimmun.* 39 (2012) 15–26, <https://doi.org/10.1016/j.jaut.2012.03.001>.
- [174] M.R. Arubuckle, M.T. McClain, M.V. Rubertone, R.H. Scofield, G.J. Dennis, J. A. James, J.B. Harley, Development of autoantibodies before the clinical onset of systemic lupus erythematosus, *N. Engl. J. Med.* 349 (2003) 1526–1533, <https://doi.org/10.1056/NEJMoa021933>.
- [175] E. Theander, R. Jonsson, B. Sjöström, K. Brokstad, P. Olsson, G. Henriksson, Prediction of Sjögren's syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling, *Arthritis Rheumatol.* 67 (2015) 2427–2436, <https://doi.org/10.1002/art.39214>.
- [176] R. Jonsson, E. Theander, B. Sjöström, K. Brokstad, G. Henriksson, Autoantibodies present before symptom onset in primary Sjögren syndrome, *JAMA* 310 (2013) 1854–1855, <https://doi.org/10.1001/jama.2013.278448>.
- [177] J. Suurmond, B. Diamond, Autoantibodies in systemic autoimmune diseases: specificity and pathogenicity, *J. Clin. Invest.* 125 (2015) 2194–2202, <https://doi.org/10.1172/JCI78084>.
- [178] D.S. Pisetsky, P.E. Lipsky, New insights into the role of antinuclear antibodies in systemic lupus erythematosus, *Nat. Rev. Rheumatol.* 16 (2020) 565–579, <https://doi.org/10.1038/s41584-020-0480-7>.
- [179] J.E. Mjelle, O.P. Rekvig, J. Van Der Vlag, K.A. Fenton, Nephritogenic antibodies bind in glomeruli through interaction with exposed chromatin fragments and not with renal cross-reactive antigens, *Autoimmunity* 44 (2011) 373–383, <https://doi.org/10.3109/08916934.2010.541170>.
- [180] M.J. Mirzayan, R.E. Schmidt, T. Witte, Prognostic parameters for flare in systemic lupus erythematosus, *Rheumatology* 39 (2000) 1316–1319, <https://doi.org/10.1093/rheumatology/39.12.1316>.
- [181] G. Moroni, A. Radice, G. Giammarresi, S. Quaglini, B. Gallelli, A. Leoni, M. L. Vecchi, P. Messa, R.A. Sinico, Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis, *Ann. Rheum. Dis.* 68 (2009) 234–237, <https://doi.org/10.1136/ard.2008.094508>.
- [182] H. Bootsma, P.E. Spronk, E.J.T. Borg, E.J. Hummel, G. de Boer, P.C. Limburg, C.G. M. Kallenberg, The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long term observation, *Ann. Rheum. Dis.* 56 (1997) 661–666, <https://doi.org/10.1136/ard.56.11.661>.
- [183] C.P. Robinson, J. Brayer, S. Yamachika, T.R. Esch, A.B. Peck, C.A. Stewart, E. Peen, R. Jonsson, M.G. Humphreys-Beher, Transfer of human serum IgG to nonobese diabetic Igu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjögren's syndrome, *Proc. Natl. Acad. Sci* 95 (1998) 7538–7543, <https://doi.org/10.1073/pnas.95.13.7538>.
- [184] R.H. Scofield, S. Asfa, D. Obeso, R. Jonsson, B.T. Kurien, Immunization with short peptides from the 60-kDa Ro antigen recapitulates the serological and pathological findings as well as the salivary gland dysfunction of Sjögren's syndrome, *J. Immunol.* 175 (2005) 8409–8414, <https://doi.org/10.4049/jimmunol.175.12.8409>.
- [185] C.K. Wong, P.T.Y. Wong, L.S. Tam, E.K. Li, D.P. Chen, C.W.K. Lam, Activation profile of Toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus, *Clin. Exp. Immunol.* 159 (2010) 11–22, <https://doi.org/10.1111/j.1365-2249.2009.04036.x>.
- [186] L. Zheng, Z. Zhang, C. Yu, C. Yang, Expression of Toll-like receptors 7, 8, and 9 in primary Sjögren's syndrome, *Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endodontol.* 109 (2010) 844–850, <https://doi.org/10.1016/j.tripleo.2010.01.006>.

- [187] J. Eckl-Dorna, F.D. Batista, BCR-mediated uptake of antigen linked to TLR9 ligand stimulates B-cell proliferation and antigen-specific plasma cell formation, *Blood* 113 (2009) 3969–3977, <https://doi.org/10.1182/blood-2008-10-185421>.
- [188] E.J. Pone, J. Zhang, T. Mai, C.A. White, G. Li, J.K. Sakakura, P.J. Patel, A. Al-Qahtani, H. Zan, Z. Xu, P. Casali, BCR-signalling synergizes with TLR-signalling for induction of AID and immunoglobulin class-switching through the non-canonical NF- κ B pathway, *Nat. Commun.* 3 (2012) 767, <https://doi.org/10.1038/ncomms1769>.
- [189] D. Saadoun, B. Terrier, J. Bannock, T. Vazquez, C. Massad, I. Kang, F. Joly, M. Rosenzweig, D. Sene, P. Benech, L. Musset, D. Klatzmann, E. Meffre, P. Cacoub, Expansion of autoreactive unresponsive CD21⁻/low B cells in Sjögren's syndrome-associated lymphoproliferation, *Arthritis Rheum* 65 (2013) 1085–1096, <https://doi.org/10.1002/art.37828>.
- [190] R. Davies, I. Sarkar, D. Hammenfors, B. Bergum, P. Vogelsang, S.M. Solberg, S. Gavasso, J.G. Brun, R. Jonsson, S. Appel, Single cell based phosphorylation profiling identifies alterations in toll-like receptor 7 and 9 signaling in patients with primary Sjögren's syndrome, *Front. Immunol.* (2019) 10, <https://www.frontiersin.org/articles/10.3389/fimmu.2019.00281> (accessed February 1, 2023).
- [191] S. Wang, J. Wang, V. Kumar, J.L. Karnell, B. Naiman, P.S. Gross, S. Rahman, K. Zerrouki, R. Hanna, C. Morehouse, N. Holowecyk, H. Liu, Z. Manna, R. Goldbach-Mansky, S. Hasni, R. Siegel, M. Sanjuan, K. Streicher, M.P. Cancro, R. Kolbeck, R. Ettinger, IL-21 drives expansion and plasma cell differentiation of autoreactive CD11c^{hi}T-bet⁺ B cells in SLE, *Nat. Commun.* 9 (2018) 1758, <https://doi.org/10.1038/s41467-018-03750-7>.
- [192] M.L. Golinski, M. Demeules, C. Derambure, G. Riou, M. Maho-Vaillant, O. Boyer, P. Joly, S. Calbo, CD11c⁺ B cells are mainly memory cells, precursors of antibody secreting cells in healthy donors, *Front. Immunol.* (2020) 11, <https://www.frontiersin.org/articles/10.3389/fimmu.2020.00032> (accessed November 9, 2022).
- [193] A.P. Risselada, M.F. Looije, A.A. Kruize, J.W.W.J. Bijlsma, J.A.G. van Roon, The role of ectopic germinal centers in the immunopathology of primary Sjögren's syndrome: a systematic review, *Semin. Arthritis Rheum.* 42 (2013) 368–376, <https://doi.org/10.1016/j.semarthrit.2012.07.003>.
- [194] S. Jamaly, M. Rakae, R. Abdi, G.C. Tsokos, K.A. Fenton, Interplay of immune and kidney resident cells in the formation of tertiary lymphoid structures in lupus nephritis, *Autoimmun. Rev.* 20 (2021), 102980, <https://doi.org/10.1016/j.autrev.2021.102980>.
- [195] X. Zhang, E. Lindwall, G. Gauthier, J. Lyman, N. Spencer, A. Alarakhia, A. Fraser, S. Ing, M. Chen, T. Webb-Deitge, J. Zakem, W. Davis, Y.S. Choi, R. Quinet, Circulating CXCR5+CD4+ helper T cells in systemic lupus erythematosus patients share phenotypic properties with germinal center follicular helper T cells and promote antibody production, *Lupus* 24 (2015) 909–917, <https://doi.org/10.1177/0961203314567750>.
- [196] K.M. Chavele, E. Merry, M.R. Ehrenstein, Cutting edge: circulating plasmablasts induce the differentiation of human T follicular helper cells via IL-6 production, *J. Immunol.* 194 (2015) 2482–2485, <https://doi.org/10.1093/jimmunol.1401190>.
- [197] E. Pontarini, W.J. Murray-Brown, C. Croia, D. Lucchesi, J. Conway, F. Rivellese, L. Fossati-Jimack, E. Astorri, E. Prediletto, E. Corsiero, F.R. Delvecchio, R. Coleby, E. Gelbhardt, A. Bono, C. Baldini, I. Puxeddu, P. Ruscitti, R. Giacomelli, F. Barone, B. Fisher, S.J. Bowman, S. Colafrancesco, R. Priori, N. Sutcliffe, S. Challacombe, G. Carlesso, A. Tappuni, C. Pitzalis, M. Bombardieri, Unique expansion of IL-21+ Tfh and Tph cells under control of ICOS identifies Sjögren's syndrome with ectopic germinal centres and MALT lymphoma, *Ann. Rheum. Dis.* 79 (2020) 1588–1599, <https://doi.org/10.1136/annrheumdis-2020-217646>.
- [198] A. Dupré, J. Pascaud, E. Rivière, A. Paoletti, B. Ly, M. Mingueneau, X. Mariette, G. Nocturne, Association between T follicular helper cells and T peripheral helper cells with B-cell biomarkers and disease activity in primary Sjögren syndrome, *RMD Open* 7 (2021), e001442, <https://doi.org/10.1136/rmdopen-2020-001442>.
- [199] R. Banchereau, S. Hong, B. Cantarel, N. Baldwin, J. Baisch, M. Edens, A. M. Cepika, P. Acs, J. Turner, E. Anguiano, P. Vinod, S. Khan, G. Obermoser, D. Blankenship, E. Wakeland, L. Nassi, A. Gotte, M. Punaro, Y.J. Liu, J. Banchereau, J. Rossello-Urgell, T. Wright, V. Pascual, Personalized immunomonitoring uncovers molecular networks that stratify lupus patients, *Cell* 165 (2016) 551–565, <https://doi.org/10.1016/j.cell.2016.03.008>.
- [200] M. Nakano, M. Ota, Y. Takeshima, Y. Iwasaki, H. Hatano, Y. Nagafuchi, T. Itamiya, J. Maeda, R. Yoshida, S. Yamada, A. Nishiwaki, H. Takahashi, H. Takahashi, Y. Akutsu, T. Kusuda, H. Suetsugu, L. Liu, K. Kim, X. Yin, S.Y. Bang, Y. Cui, H.S. Lee, H. Shoda, X. Zhang, S.C. Bae, C. Terao, K. Yamamoto, T. Okamura, K. Ishigaki, K. Fujio, Distinct transcriptome architectures underlying lupus establishment and exacerbation, *Cell* 185 (2022) 3375–3389, <https://doi.org/10.1016/j.cell.2022.07.021>, e21.
- [201] J. Suurmond, Y. Atisha-Fregoso, A.N. Barlev, S.A. Calderon, M.C. Mackay, C. Aranow, B. Diamond, Patterns of ANA⁺ B cells for SLE patient stratification, *JCI Insight* 4 (2019), <https://doi.org/10.1172/jci.insight.127885>.
- [202] A.M. Jacobi, H. Mei, B.F. Hoyer, I.M. Mumtaz, K. Thiele, A. Radbruch, G. R. Burmester, F. Hiepe, T. Dörner, HLA-DRhigh/CD27high plasmablasts indicate active disease in patients with systemic lupus erythematosus, *Ann. Rheum. Dis.* 69 (2010) 305–308, <https://doi.org/10.1136/ard.2008.096495>.
- [203] L. Ostendorf, M. Burns, P. Durek, G.A. Heinz, F. Heinrich, P. Garantziotis, P. Enghard, U. Richter, R. Biesen, U. Schneider, F. Knebel, G. Burmester, A. Radbruch, H.E. Mei, M.F. Mashreghi, F. Hiepe, T. Alexander, Targeting CD38 with daratumumab in refractory systemic lupus erythematosus, *N. Engl. J. Med.* 383 (2020) 1149–1155, <https://doi.org/10.1056/NEJMoa2023325>.
- [204] C.M. Tipton, C.F. Fucile, J. Darce, A. Chida, T. Ichikawa, I. Gregoret, S. Schieferl, J. Hom, S. Jenks, R.J. Feldman, R. Mehr, F.E.-H. Lee, W.C. Cheung, A. F. Rosenberg, I. Sanz, Diversity, cellular origin and autoreactivity of antibody-secreting cell population expansions in acute systemic lupus erythematosus, *Nat. Immunol.* 16 (2015) 755–765, <https://doi.org/10.1038/ni.3175>.
- [205] E.D. Papadimitrakaki, C. Choulaki, E. Koutala, G. Bertisias, C. Tsatsanis, I. Gergianaki, A. Raptopoulou, H.D. Kritikos, C. Mamlaki, P. Sidiropoulos, D. T. Boumpas, Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process, *Arthritis Rheum.* 54 (2006) 3601–3611, <https://doi.org/10.1002/art.22197>.
- [206] M. Kashgarian, The role of the kidney biopsy in the treatment of lupus nephritis, *Ren. Fail.* 18 (1996) 765–773, <https://doi.org/10.3109/08860229609047705>.
- [207] E. Crickx, F. Tamirou, T. Huscenot, N. Costedoat-Chalumeau, M. Rabant, A. Karras, A. Robbins, T. Fadeev, V. Le Guern, P. Remy, A. Hummel, S. Aydin, B. Lauwerys, J.C. Weill, C.A. Reynaud, F. Houssiau, M. Mahévas, Molecular signatures of kidney antibody-secreting cells in lupus patients with active nephritis upon immunosuppressive therapy, *Arthritis Rheumatol.* 73 (2021) 1461–1466, <https://doi.org/10.1002/art.41703>.
- [208] Q. Cheng, I.M. Mumtaz, L. Khodadadi, A. Radbruch, B.F. Hoyer, F. Hiepe, Autoantibodies from long-lived 'memory' plasma cells of NZB/W mice drive immune complex nephritis, *Ann. Rheum. Dis.* 72 (2013) 2011–2017, <https://doi.org/10.1136/annrheumdis-2013-203455>.
- [209] A. Arazi, D.A. Rao, C.C. Berthier, A. Davidson, Y. Liu, P.J. Hoover, A. Chicoine, T. M. Eisenhaure, A.H. Jonsson, S. Li, D.J. Lieb, F. Zhang, K. Slowikowski, E. P. Browne, A. Noma, D. Sutherby, S. Steelman, D.E. Smilek, P. Tosta, W. Appuzzese, E. Massarotti, M. Dall'Era, M. Park, D.L. Kamen, R.A. Furie, F. Payan-Schober, W.F. Pendergraft, E.A. McInnis, J.P. Buyon, M.A. Petri, C. Putterman, K.C. Kalunian, E.S. Woodle, J.A. Lederer, D.A. Hildeman, C. Nusbaum, S. Raychaudhuri, M. Kretzler, J.H. Anolik, M.B. Brenner, D. Wofsy, N. Hachohen, B. Diamond, Accelerating Medicines Partnership in SLE network, the immune cell landscape in kidneys of patients with lupus nephritis, *Nat. Immunol.* 20 (2019) 902–914, <https://doi.org/10.1038/s41590-019-0398-x>.
- [210] M. Mingueneau, S. Boudaoud, S. Haskett, T.L. Reynolds, G. Nocturne, E. Norton, X. Zhang, M. Constant, D. Park, W. Wang, T. Lazure, C. Le Pajolec, A. Ergun, X. Mariette, Cytometry by time-of-flight immunophenotyping identifies a blood Sjögren's signature correlating with disease activity and glandular inflammation, *J. Allergy Clin. Immunol.* 137 (2016) 1809–1821, <https://doi.org/10.1016/j.jaci.2016.01.024>, e12.
- [211] L. Jin, D. Yu, X. Li, N. Yu, X. Li, Y. Wang, Y. Wang, CD4+CXCR5+ follicular helper T cells in salivary gland promote B cells maturation in patients with primary Sjögren's syndrome, *Int. J. Clin. Exp. Pathol.* 7 (2014) 1988–1996.
- [212] S. Liu, Y. Yang, L. Zeng, L. Wang, C. He, Z. Chen, J. Sun, T. Lyu, M. Wang, H. Chen, F. Zhang, TOX promotes follicular helper T cell differentiation in patients with primary Sjögren's syndrome, *Rheumatology* (2022) keac304, <https://doi.org/10.1093/rheumatology/keac304>.
- [213] M. Hale, D.J. Rawlings, S.W. Jackson, The long and the short of it: insights into the cellular source of autoantibodies as revealed by B cell depletion therapy, *Curr. Opin. Immunol.* 55 (2018) 81–88, <https://doi.org/10.1016/j.coi.2018.10.008>.
- [214] V. Devauchelle-Pensec, Y. Pennec, J. Morvan, J.O. Pers, C. Daridon, S. Jousse-Joulin, A. Roudaut, C. Jamin, Y. Renaudineau, I.Q. Roué, B. Cochenier, P. Youinou, A. Saraux, Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20), *Arthritis Care Res.* 57 (2007) 310–317, <https://doi.org/10.1002/art.22536>.
- [215] G.M. Verstappen, F.G.M. Kroese, P.M. Meiners, O.B. Cornth, M.G. Huitema, E. A. Haacke, B. van der Vegt, S. Arends, A. Vissink, H. Bootsma, W.H. Abdulahad, B cell depletion therapy normalizes circulating follicular Th cells in primary Sjögren syndrome, *J. Rheumatol.* 44 (2017) 49–58, <https://doi.org/10.3899/jrheum.160313>.
- [216] A. Vissink, H. Bootsma, Refining the classification criteria for primary Sjögren syndrome, *Nat. Rev. Rheumatol.* 13 (2017) 10–12, <https://doi.org/10.1038/nrrheum.2016.208>.
- [217] K. Skarstein, J.L. Jensen, H. Galtung, R. Jonsson, K. Brokstad, L.A. Aqrabi, Autoantigen-specific B cells and plasma cells are prominent in areas of fatty infiltration in salivary glands of patients with primary Sjögren's syndrome, *Autoimmunity* 52 (2019) 242–250, <https://doi.org/10.1080/08916934.2019.1684475>.
- [218] E.A. Szyszko, L.A. Aqrabi, R. Jonsson, K.A. Brokstad, K. Skarstein, Non-proliferating plasma cells detected in the salivary glands and bone marrow of autoimmune NOD.B10.H2b mice, a model for primary Sjögren's syndrome, *Autoimmunity* 49 (2016) 41–49, <https://doi.org/10.3109/08916934.2015.1079820>.
- [219] A.L. Tomi, R. Belkhir, G. Nocturne, F. Desmoulin, E. Berge, S. Pavy, C. Miceli-Richard, X. Mariette, R. Seror, Monoclonal gammopathy and risk of lymphoma and multiple myeloma in patients with primary Sjögren's syndrome, *Arthritis Rheumatol.* (2015), <https://doi.org/10.1002/art.39534> n/a-n/a.
- [220] A. Sebastian, M. Madej, M. Sebastian, A. Butrym, P. Woytala, A. Hałóń, P. Willand, Prevalence and clinical presentation of lymphoproliferative disorder in patients with primary Sjögren's syndrome, *Rheumatol. Int.* 40 (2020) 399–404, <https://doi.org/10.1007/s00296-020-04522-7>.
- [221] C.M. McShane, L.J. Murray, O. Landgren, M.A. O'Rourke, N. Korde, A. T. Kunzmann, M.R. Ismail, L.A. Anderson, Prior autoimmune disease and risk of monoclonal gammopathy of undetermined significance and multiple myeloma: a systematic review, *Cancer Epidemiol. Biomarkers Prev.* 23 (2014) 332–342, <https://doi.org/10.1158/1055-9965.EPI-13-0695>.
- [222] J. Mofors, A. Björk, K.E. Smedby, M. Kvarnström, H. Forsblad-d'Elia, S. Magnusson-Bucher, P. Eriksson, T. Mandl, E. Bäcklund, G. Nordmark, M. Wahren-Herlenius, Increased risk of multiple myeloma in primary Sjögren's

- syndrome is limited to individuals with Ro/SSA and La/SSB autoantibodies, *Ann. Rheum. Dis.* 79 (2020) 307–308, <https://doi.org/10.1136/annrheumdis-2019-216287>.
- [223] N. Hamza, H. Bootsma, S. Yuvaraj, F.K.L. Spijkervet, E.A. Haacke, R.P.E. Pollard, A. Visser, A. Vissink, C.G.M. Kallenberg, F.G.M. Kroese, N.A. Bos, Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy, *Ann. Rheum. Dis.* 71 (2012) 1881–1887, <https://doi.org/10.1136/annrheumdis-2011-201189>.
- [224] M.G.A. Broeren, J.J. Wang, G. Balzaretto, P.J.T.A. Groenen, B.D.C. van Schaik, T. Chataway, C. Kaffa, S. Bervoets, K.M. Hebeda, G. Bounova, G.J.M. Pruijn, T. P. Gordon, N.D. Vries, R.M. Thurlings, Proteogenomic analysis of the autoreactive B cell repertoire in blood and tissues of patients with Sjögren's syndrome, *Ann. Rheum. Dis.* 81 (2022) 644–652, <https://doi.org/10.1136/annrheumdis-2021-221604>.
- [225] S. Gandolfi, J.P. Laubach, T. Hideshima, D. Chauhan, K.C. Anderson, P. G. Richardson, The proteasome and proteasome inhibitors in multiple myeloma, *Cancer Metastasis Rev.* 36 (2017) 561–584, <https://doi.org/10.1007/s10555-017-9707-8>.
- [226] T. Alexander, R. Sarfert, J. Klotsche, A.A. Kühn, A. Rubbert-Roth, H.M. Lorenz, J. Rech, B.F. Hoyer, Q. Cheng, A. Waka, A. Taddeo, M. Wiesener, G. Schett, G. R. Burmester, A. Radbruch, F. Hiepe, R.E. Voll, The proteasome inhibitor bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus, *Ann. Rheum. Dis.* 74 (2015) 1474–1478, <https://doi.org/10.1136/annrheumdis-2014-206016>.
- [227] T. Alexander, Q. Cheng, J. Klotsche, L. Khodadadi, A. Waka, R. Biesen, B.F. Hoyer, G.R. Burmester, A. Radbruch, F. Hiepe, Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors, *Eur. J. Immunol.* 48 (2018) 1573–1579, <https://doi.org/10.1002/eji.201847492>.
- [228] E. Pancheri, V. Guglielmi, G.M. Wilczynski, M. Malatesta, P. Tonin, G. Tomelleri, D. Nowis, G. Vattemi, Non-hematologic toxicity of bortezomib in multiple myeloma: the neuromuscular and cardiovascular adverse effects, *Cancers (Basel)* 12 (2020) 2540, <https://doi.org/10.3390/cancers12092540>.
- [229] J. Jabez-Ocampo, Y. Atisha-Fregoso, L. Llorente, Refractory primary Sjögren syndrome successfully treated with bortezomib, *JCR J. Clin. Rheumatol.* 21 (2015) 31–32, <https://doi.org/10.1097/RHU.0000000000000210>.
- [230] N.W.C.J. van de Donk, P.G. Richardson, F. Malavasi, CD38 antibodies in multiple myeloma: back to the future, *Blood* 131 (2018) 13–29, <https://doi.org/10.1182/blood-2017-06-740944>.
- [231] S. Lonial, M. Dimopoulos, A. Palumbo, D. White, S. Grosicki, I. Spicka, A. Walter-Croneck, P. Moreau, M.V. Mateos, H. Magen, A. Belch, D. Reece, M. Beksac, A. Spencer, H. Oakervee, R.Z. Orłowski, M. Taniwaki, C. Röllig, H. Einsele, K. L. Wu, A. Singhal, J. San-Miguel, M. Matsumoto, J. Katz, E. Bleickardt, V. Poulart, K.C. Anderson, P. Richardson, Elotuzumab therapy for relapsed or refractory multiple myeloma, *N. Engl. J. Med.* 373 (2015) 621–631, <https://doi.org/10.1056/NEJMoa1505654>.
- [232] S. Lonial, H.C. Lee, A. Badros, S. Trudel, A.K. Nooka, A. Chari, A.O. Abdallah, N. Callander, N. Lendvai, D. Sborov, A. Suvannasankha, K. Weisel, L. Karlin, E. Libby, B. Arnulf, T. Facon, C. Hulin, K.M. Kortüm, P. Rodríguez-Otero, S. Z. Usmani, P. Hari, R. Baz, H. Quach, P. Moreau, P.M. Voorhees, I. Gupta, A. Hoos, E. Zhi, J. Baron, T. Piontek, E. Lewis, R.C. Jewell, E.J. Dettman, R. Popat, S.D. Esposti, J. Opalinska, P. Richardson, A.D. Cohen, Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study, *Lancet Oncol.* 21 (2020) 207–221, [https://doi.org/10.1016/S1470-2045\(19\)30788-0](https://doi.org/10.1016/S1470-2045(19)30788-0).
- [233] K.S. Campbell, A.D. Cohen, T. Pazina, Mechanisms of NK cell activation and clinical activity of the therapeutic SLAMF7 antibody, elotuzumab in multiple myeloma, *Front. Immunol.* 9 (2018) 2551, <https://doi.org/10.3389/fimmu.2018.02551>.
- [234] T. Gogishvili, S. Danhof, S. Prommersberger, J. Rydzek, M. Schreder, C. Brede, H. Einsele, M. Hudecek, SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes, *Blood* 130 (2017) 2838–2847, <https://doi.org/10.1182/blood-2017-04-778423>.
- [235] C.P.M. Verkleij, K.A. Frerichs, M. Broekmans, S. Absalah, P.W.C. Maas-Bosman, S. Kruyswijk, I.S. Nijhof, T. Mutis, S. Zweegman, N.W.C.J. van de Donk, T-cell redirecting bispecific antibodies targeting BCMA for the treatment of multiple myeloma, *Oncotarget* 11 (2020) 4076–4081, <https://doi.org/10.18632/oncotarget.27792>.
- [236] M. Yalcin Mutlu, J. Wacker, K. Tascilar, J. Taubmann, B. Manger, G. Krönke, G. Schett, D. Simon, Effective and safe treatment of anti-CD38 therapy in systemic lupus erythematosus-associated refractory cerebral vasculitis induces immune tolerance, *Rheumatology* (2022) keac393, <https://doi.org/10.1093/rheumatology/keac393>.
- [237] K.A. Frerichs, P.W.C. Bosman, J.F. van Velzen, P.L.A. Fraaij, M.P.G. Koopmans, G. F. Rimmelzwaan, I.S. Nijhof, A.C. Bloem, T. Mutis, S. Zweegman, N.W.C.J. van de Donk, Effect of daratumumab on normal plasma cells, polyclonal immunoglobulin levels, and vaccination responses in extensively pre-treated multiple myeloma patients, *Haematologica* 105 (2020) e302–e306, <https://doi.org/10.3324/haematol.2019.231860>.
- [238] F. (Xiaohu) Fan, W. Zhao, J. Liu, A. He, Y. Chen, X. Cao, N. Yang, B. Wang, P. Zhang, Y. Zhang, F. Wang, B. Lei, L. Gu, X. Wang, Q. Zhuang, W. Zhang, Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma, *J. Clin. Oncol.* 35 (2017), https://doi.org/10.1200/JCO.2017.35.18_suppl.LBA3001. LBA3001–LBA3001.
- [239] J. Xu, L.J. Chen, S.S. Yang, Y. Sun, W. Wu, Y.F. Liu, J. Xu, Y. Zhuang, W. Zhang, X. Q. Weng, Y. Wu, Y. Wang, J. Wang, H. Yan, W.B. Xu, H. Jiang, J. Du, X.Y. Ding, B. Li, J.M. Li, W.J. Fu, J. Zhu, L. Zhu, Z. Chen, X.H. (Frank) Fan, J. Hou, J.Y. Li, J. Q. Mi, S.J. Chen, Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma, *Proc. Natl. Acad. Sci.* 116 (2019) 9543–9551, <https://doi.org/10.1073/pnas.1819745116>.
- [240] S.A. Ali, V. Shi, I. Maric, M. Wang, D.F. Stroncek, J.J. Rose, J.N. Brudno, M. Stetler-Stevenson, S.A. Feldman, B.G. Hansen, V.S. Fellowes, F.T. Hakim, R. E. Gress, J.N. Kochenderfer, T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma, *Blood* 128 (2016) 1688–1700, <https://doi.org/10.1182/blood-2016-04-711903>.
- [241] A. Mackensen, F. Müller, D. Mougiakakos, S. Böltz, A. Wilhelm, M. Aigner, S. Völkl, D. Simon, A. Kleyer, L. Munoz, S. Kretschmann, S. Kharboutli, R. Gary, H. Reimann, W. Rösler, S. Uderhardt, H. Bang, M. Herrmann, A.B. Ekcici, C. Buettner, K.M. Habenicht, T.H. Winkler, G. Krönke, G. Schett, Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus, *Nat. Med.* (2022) 1–9, <https://doi.org/10.1038/s41591-022-02017-5>.
- [242] V.G. Bhoj, D. Arhontoulis, G. Wertheim, J. Capobianchi, C.A. Callahan, C. T. Ellebrecht, A.E. Obstfeld, S.F. Lacey, J.J. Melenhorst, F. Nazimuddin, W. T. Hwang, S.L. Maude, M.A. Wasik, A. Bagg, S. Schuster, M.D. Feldman, D. L. Porter, S.A. Grupp, C.H. June, M.C. Milone, Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy, *Blood* 128 (2016) 360–370, <https://doi.org/10.1182/blood-2016-01-694356>.
- [243] Q. Cheng, A. Pelz, A. Taddeo, L. Khodadadi, J. Klotsche, B.F. Hoyer, T. Alexander, A. Thiel, G.R. Burmester, A. Radbruch, F. Hiepe, Selective depletion of plasma cells in vivo based on the specificity of their secreted antibodies, *Eur. J. Immunol.* 50 (2020) 284–291, <https://doi.org/10.1002/eji.201948144>.
- [244] A. Taddeo, V. Gerl, B.F. Hoyer, H.D. Chang, S. Kohler, H. Schaffert, A. Thiel, A. Radbruch, F. Hiepe, Selection and depletion of plasma cells based on the specificity of the secreted antibody, *Eur. J. Immunol.* 45 (2015) 317–319, <https://doi.org/10.1002/eji.201444993>.